*ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor alpha (FRα) expression levels

*Confirmed objective response rates (cORR) of 64.5% at the 6.4 mg/kg dose in patients with high-grade serous platinum-resistant ovarian cancer

*Median duration of response not yet reached at either dose level at median 7 months follow-up, with six-month progression-free survival rate of 61% in both groups

*Favorable tolerability profile, particularly at 6.4 mg/kg, supports continued clinical development in partnership or through a strategic collaboration

*Conference call with Zymeworks management on October 27 at 8:30 am Eastern Time (ET)

VANCOUVER, British Columbia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the randomized dose-optimization portion of its ongoing Phase 1 study evaluating ZW191, a FRα-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

The presentation highlights compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer (PROC), including patients with high-grade serous disease across all levels of FRα expression. The results demonstrate compelling response rates, durability and a favorable tolerability profile, particularly at the 6.4 mg/kg dose, further supporting the potential of ZW191 to address limitations of currently available FRα-targeted therapies and expand treatment opportunities for patients with ovarian cancer.

"We are highly encouraged by these results, which further demonstrate the differentiated clinical profile of ZW191 and its potential to deliver meaningful benefit to patients with platinum-resistant ovarian cancer," said Sabeen Mekan, M.D., Senior Vice President and Chief Medical Officer, Zymeworks. "The robust response rates observed at both doses, including meaningful activity in patients with low or negative FRα expression, reinforce the potential of ZW191 to benefit a broader patient population. Importantly, the encouraging durability of responses and favorable tolerability profile, particularly at 6.4 mg/kg, provide valuable insights to guide dose selection and the next stage of clinical development."

The analysis included efficacy and safety data from 80 patients with PROC randomized to receive ZW191 at 6.4 mg/kg (n=37) or 9.6 mg/kg (n=43) every three weeks, as of the September 10, 2026 data cutoff date. Patients were heavily pretreated, having received a median of four prior lines of therapy, with 45% receiving five or more prior lines. Median follow-up was seven months. FRα expression was assessed by immunohistochemistry and categorized as low/negative (0%-24%), intermediate (25%-74%) or high (75%-100%) based on the percentage of tumor cells with 2+ or 3+ staining intensity.

Key Findings

Among response-evaluable patients with high-grade serous PROC, ZW191 demonstrated a cORR of 64.5% at 6.4 mg/kg and 55.3% at 9.6 mg/kg, with disease control rates of 100% and 92.1%, respectively. These findings demonstrate compelling anti-tumor activity at both doses in a heavily pretreated patient population.

ZW191 demonstrated meaningful anti-tumor activity across FRα expression in patients with high-grade serous PROC. Confirmed objective response rates were 69.2% in patients with high FRα expression, 50.0% in patients with intermediate FRα expression and 55.0% in patients with low or negative FRα expression. These findings support the potential of ZW191 to show improved efficacy than existing FRα targeted therapies in FRα high population and meaningfully benefit patients with lower expression who may not be eligible for currently approved FRα targeting therapies.

Responses to ZW191 were deep and durable, with median duration of response not yet reached at either dose. Six-month progression-free survival (PFS) was 61% in both groups, while median PFS was 7.9 months at 6.4 mg/kg and 9.8 months at 9.6 mg/kg in patients with high-grade serous PROC. At the time of data cutoff, 45% of patients remained on treatment, and PFS data continue to mature, especially at 6.4 mg/kg.

ZW191 continued to demonstrate a favorable tolerability profile, particularly at 6.4 mg/kg. Grade 3 or higher treatment-related adverse events occurred in 22% of patients receiving 6.4 mg/kg compared with 44% at 9.6 mg/kg. Treatment-emergent adverse events leading to dose reductions occurred in 5% and 33% of patients, respectively, while discontinuations due to adverse events occurred in 14% and 19%. No deaths due to treatment-emergent adverse events were reported in either treatment group. The overall safety profile was manageable and supports continued clinical development.

"These results are particularly promising for patients with platinum-resistant ovarian cancer who have exhausted available treatment options," said Jung-Yun Lee, M.D., Ph.D., Yonsei Cancer Center and Severance Hospital, Seoul, Republic of South Korea, and primary investigator who presented the results at ESMO 2026. "We observed substantial anti-tumor activity in patients who had received multiple prior therapies, including meaningful responses across high, intermediate and low or negative FRα expression levels. The encouraging durability of responses, together with the favorable safety profile observed at the lower dose, suggests ZW191 has the potential to become an important new treatment option for patients with this difficult-to-treat disease."

The findings demonstrate encouraging anti-tumor activity across the 6.4 mg/kg and 9.6 mg/kg dose levels, with a more favorable tolerability profile at 6.4 mg/kg. These results will inform optimal dose selection for further clinical development.

ZW191's differentiated profile, including its novel FRα-targeting antibody, proprietary topoisomerase I inhibitor payload, ZD06519, and high drug-to-antibody ratio, supports its potential to address key limitations of existing therapies and broaden the applicability of FRα-targeted treatment approaches.

Investor Call Details

Zymeworks invites investors and the general public to view and listen to a live webcast of its conference call with investment analysts at 8:30 am ET on October 27, 2026.

Dial-in details and webcast link are available on Zymeworks' website at https://ir.zymeworks.com/events-and-presentations. A webcast replay of the call will be available on the Zymeworks website within 24 hours following the conclusion of the live call and will be archived for a limited period.

About ZW191

ZW191 is an antibody-drug conjugate engineered to target a protein called folate receptor-⍺ found in ~75% of high-grade serous ovarian carcinomas,1 over 50% of endometrial cancers,2,3 and ~70% of lung adenocarcinomas4. ZW191's differentiated design strongly supports its ability to internalize into FR⍺-expressing cells with the potential to release bystander active topoisomerase-1 inhibitor (ZD06519), a novel proprietary payload developed by Zymeworks to kill tumor cells.

The Company has engaged MTS Healthcare to evaluate strategic partnering opportunities to fund further development for ZW191 with the objective of maximizing long-term value.

About Zymeworks Inc.

Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. The Company's asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI? (revefenacin), with a differentiated internal research and development engine. Zymeworks' portfolio also includes Ziihera? (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks' proprietary antibody engineering technologies.

Zymeworks is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric? platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. These capabilities, together with Zymeworks' integrated drug development expertise, enable the Company to develop differentiated therapeutics and create value through both internal innovation and strategic partnerships.

For more information about Zymeworks, its portfolio and pipeline, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Forward-looking statements in this press release include, but are not limited to, statements that relate to the potential safety profile and therapeutic effects of ZW191; Zymeworks' development of product candidates; status of studies and the related data; anticipated clinical data presentations; Zymeworks' implementation of its long-term strategy; and other information that is not historical information. When used herein, words such as "plan", "believe", "expect", "may", "continue", "anticipate", "potential", "will", "on track", "progress", "preserve", "intend", "could", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks' current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain.

Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks' or its partners' product candidates, including ZW191, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not achieve milestones or receive additional payments or royalties under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of global and regional geopolitical or public health developments on Zymeworks' business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks' behalf; zanidatamab may not be successfully commercialized; Zymeworks' business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented; Zymeworks' evolution of its business strategy may not deliver meaningful shareholder returns; Zymeworks may be unsuccessful in actively managing and/or aggregating revenue generating assets alongside its active R&D operations; ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks' or its collaborators' product candidates, including ZW191; Zymeworks' assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under "Risk Factors" in Zymeworks' quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

---

1 Kobel, M., Madore, J., Ramus, S. et al., Br J Cancer 111, 2297?2307 (2014).

2 May B, Conway N, Truong T, Linhart S, et al. FRα, B7-H4, & HER2 Expression in Endometrial Cancer: Assessing the Promise of Antibody Drug Conjugate Therapies. Presented at: SGO 2025 Winter Meeting; January 30 - February 1, 2025; Whistler, British Columbia, Canada.

3 Senol S, Ceyran AB, Aydin A, Zemheri E, Ozkanli S, K?semetin D, Sehitoglu I, Akalin I. Folate receptor α expression and significance in endometrioid endometrium carcinoma and endometrial hyperplasia. Int J Clin Exp Pathol. 2015 May 1;8(5):5633-41.

4 O'Shannessy DJ, et al., Oncotarget. 2012 Apr; 3(4):414-25.

Copyright 2026 GlobeNewswire, Inc.

BANGKOK, THAILAND - Media OutReach Newswire - 24 October 2026 - Makers of the capacitors, magnets and battery materials inside AI servers and electric vehicles (EVs) are lining up to invest in Thailand.

Since 2023, they have filed 35 advanced materials projects worth about $690 million (23.5 billion baht) with the Thailand Board of Investment (BOI), the government's investment promotion agency. Surging demand for AI, EVs, and clean energy is pushing global suppliers to build upstream capacity in the country.

The projects, filed through the first half of 2026, cover multilayer ceramic capacitors (MLCCs), thermal graphite films, high-performance ceramics, battery and fuel-cell materials, neodymium magnets, glass and quartz fabrics for printed circuit boards, and nanomaterials for precision manufacturing. Together they mark a shift for one of Southeast Asia's largest economies from downstream assembly toward the high-value materials on which future industries are built.

In AI computing and clean energy, lighter, more heat-resistant and more conductive materials determine how well devices perform. MLCCs are essential components in products from smartphones to AI servers, and a single high-end server can use up to 30,000 of them.

"The world is moving toward products that are smaller and lighter, yet stronger and more efficient," said Mr. Narit Therdsteerasukdi, Secretary General of the Thailand Board of Investment. "Producing advanced materials in Thailand is key to building sustainable industrial capacity, reducing reliance on imports, and opening the door for Thai companies to join higher-value supply chains."

Thailand is already a production base for leading component makers, including Japan's Murata Electronics, which holds more than 35 percent of the global MLCC market, and Kyocera AVX Components, the world's top tantalum capacitor maker. Among the new projects, Taiwan's Fultech Fiber Glass makes glass fabric for printed circuit boards, including high-performance grades for AI servers. Jones Tech produces synthetic and natural graphite films that carry heat away from electronic devices.

Beyond electronics, the projects strengthen supply chains for electric vehicles, batteries, and clean energy, from BGN Thai's coated foils for lithium-ion batteries and Phinis Well's neodymium magnets for EV motors to Xinyuan Graphite's bipolar plates for hydrogen fuel cells.

CoorsTek Advanced Materials, a subsidiary of US-based CoorsTek - a global leader in engineered ceramics for the semiconductor and aerospace industries - has invested in producing ceramics for automotive pressure sensors and silicon nitride balls for hybrid bearings in EVs and wind turbines. Golden Egret Cemented Carbide is making tungsten carbide powders for precision cutting tools, reinforcing Thailand's base for high-precision manufacturing.

"The advanced materials industry taking root in Thailand today is the foundation of tomorrow's supply chains in electronics, EVs, batteries, and clean energy," Mr. Narit said. "The BOI will keep building this investment base, strengthening upstream materials and components, and supporting R&D, technology, and workforce development, to move Thailand from downstream to upstream production and make it the region's advanced materials hub."

Note: USD conversions are based on the Bank of Thailand's average selling rate of approximately 33.76 baht per USD.

Thailand Board of Investment (BOI)

Established in 1966, the Thailand Board of Investment (BOI) has spent six decades promoting high-value investment from both foreign and Thai investors, strengthening the country's competitiveness and driving its transition toward a sustainable, balanced new economy.

Investment Services Center - PR Section, Office of the Board of Investment (BOI)

555 Vibhavadi-Rangsit Road, Chatuchak, Bangkok 10900 Tel. +66 (0) 2553 8111, Fax +66 (0) 2553 8222

The issuer is solely responsible for the content of this announcement.

Hashtags: #Thailandboardofinvestment #BOI #FDI #Investment

https://www.boi.go.th/en/index/

SHANGHAI, China, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies,

Announced that the first patient dosing has been completed in a randomized, open-label, multicenter phase 3 clinical study of the company's product, a recombinant humanized anti-CD20/CD3 bispecific antibody (code: JS203),

In combination with chemotherapy compared to rituximab in combination with chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) (the JS203-003-III-DLBCL Study; NCT07808827). This study is the first registrational clinical study for JS203.

DLBCL is one of the most common types of non-Hodgkin lymphoma (NHL), accounting for approximately 40% of adult NHL cases in China. According to GLOBOCAN 2022 statistics, there are approximately 45,000 new cases of DLBCL in China each year, and the incidence rate shows a slow increasing trend. DLBCL is characterized by high aggressiveness and rapid progression. A retrospective study in an Asian population showed that, even after active treatment, patients with relapsed or refractory DLBCL had a median overall survival (mOS) of over one year and a 5-year survival rate of approximately 30%, which necessitates the exploration of more proactive and effective treatment options.

JS203 is a recombinant humanized anti-CD20/CD3 bispecific antibody self-developed by Junshi Biosciences. It consists of anti-CD20 segment and anti-CD3 segment. By associating and activating lymphoma cells (binding to CD20) and T cells (binding to CD3), JS203 can enable T cells to kill lymphoma cells effectively.

Results from a phase 1 clinical study showed that, for JS203 monotherapy at the recommended phase 2 dose (RP2D) administered with step-up dosing (SUD) to 30 mg for the treatment of patients with CD20-positive relapsed or refractory B-cell non-Hodgkin lymphoma, the objective response rate (ORR) reached 72.4%. Among patients with DLBCL, the ORR was 69.7%, and the complete response rate CRR was 39.4%, with persistent relief observed. Meanwhile, the overall safety profile was manageable, with a cytokine release syndrome (CRS) incidence rate of only 27.3% and no occurrence of immune effector cell-associated neurotoxicity syndrome (ICANS).

The JS203-003-III-DLBCL Study is a randomized, open-label, multicenter phase 3 clinical trial, with Professor Yuqin SONG of Beijing Cancer Hospital serving as the principal investigator. It aims to compare the efficacy and safety of JS203 in combination with chemotherapy compared to rituximab in combination with chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma. The study plans to enroll 282 subjects, with overall survival (OS) as its primary endpoint. This study is the first registrational clinical study for JS203.

The JS203-003-III-DLBCL study team commented: "Early clinical studies have shown encouraging efficacy and a favorable safety profile for JS203 in combination with chemotherapy in patients with R/R DLBCL, reinforcing our confidence in the ongoing Phase 3 study. We are committed to advancing the study with rigor and efficiency, with the aim of making a new treatment option available to patients as soon as possible."

About JS203

JS203 is a recombinant humanized anti-CD20/CD3 bispecific antibody self-developed by Junshi Biosciences. CD20 is a B lymphocyte restricted differentiation antigen and one of the most successful targets for B-cell lymphoma treatment. CD3 is an important marker on the surface of T cells, and the main mechanism of T cell engaging bispecific antibodies is using CD3 as a mediator to activate T cells to specifically attack tumor cells. JS203 consists of anti-CD20 segment and anti-CD3 segment. By associating and activating lymphoma cells (binding to CD20) and T cells (binding to CD3), JS203 can enable T cells to kill lymphoma cells effectively. To date, a Phase 3 clinical study evaluating JS203 in combination with chemotherapy versus rituximab in combination with chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) is ongoing.

About Junshi Biosciences

Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. With our outstanding capacity for innovative drug discovery, strong biotechnology R&D capability, and large-scale production capacity, we have successfully developed a drug candidate portfolio with global competitiveness and a well-structured research pipeline, which covers therapeutic areas including cancer, autoimmune, metabolic, and infectious diseases. Our innovative field spans cutting-edge therapeutic modalities, including mAbs, small-molecule drugs, ADCs, bsAb/msAb, fusion proteins, nucleic acid drugs and vaccines.

Five of the company's products have received marketing authorizations in China and international markets, one of which is toripalimab, China's domestically developed anti-PD-1 monoclonal antibody. Toripalimab has been approved in over 50 countries and regions including China, the US, and Europe.

With a mission of "providing patients with world-class, trustworthy, affordable, and innovative drugs," Junshi Biosciences is "In China, For Global." The company currently employs more than 3,000 people worldwide. Headquartered in Shanghai, China, it has a business presence in multiple countries and regions around the world. For more information, please visit: http://www.junshipharma.com.

Copyright 2026 GlobeNewswire, Inc.

*The 2026 iCAUR International User Summit opened on October 19 in Wuhu, China, under the theme "Classic Never Fades | Make It Yours."

*The iCAUR V25 made its global debut and officially went on sale worldwide. Together with the V23 and V27, it rounds out the V-Series lineup, bringing the Future Classic Design concept to life across a comprehensive product portfolio.

*Three officially customized V-Series models will enter global markets. At the summit, 20 customized vehicles were showcased, highlighting the creativity of users from different communities and markets.

WUHU, China, Oct. 23, 2026 (GLOBE NEWSWIRE) -- The 2026 iCAUR International User Summit opened in Wuhu, China, on October 19, bringing together more than 500 user representatives from around the world, alongside partners and international media.

Under the theme "Classic Never Fades | Make It Yours," the five-day event brings together product experiences, vehicle customization, user stories and ecosystem activities, highlighting how iCAUR connects its design philosophy with the interests and creativity of users around the world.

The summit showcases the iCAUR V25, three officially customized V-Series models, and 20 customized vehicles. Visitors can also explore the iCAUR brand showroom, take part in a smart factory tour, and experience the V-Series through multi-scenario test drives. The event also marks the introduction of iCAUR's first group of Brand Ambassadors and highlights the next phase of its global user engagement initiative, Club Connect. Through these activities, iCAUR brings together three key elements of its brand: Future Classic Design, customization and a growing network of users who help shape the brand's development.

Building a Global Brand Through Products and Local Connections

Since its launch, iCAUR has expanded into more than 40 countries and regions worldwide. The V23 has surpassed 100,000 units in cumulative global sales and received the Red Dot Design Award in 2026, while the V27 won the Best Interior Design Award in the Premium Car Category at the 2026 Torino Automotive Design Award (TADA).

These milestones mark an important stage in the brand's international development. As iCAUR continues to expand into new markets, it is also working with local partners to strengthen sales and service networks and build lasting relationships with users.

At the summit, Ronna, CEO of iCAUR International, shared the brand's view that entering a market is only the beginning. Long-term growth comes from understanding users, listening to their ideas and creating experiences that give them more ways to engage with the brand.

iCAUR V25 Expands the V-Series

The iCAUR V25 takes center stage at the summit, further expanding the V-Series alongside the V23 and V27. Built around the brand's Future Classic Design philosophy, the V25 combines a distinctive boxy silhouette and classic round headlights with modern technology and capabilities for a range of driving scenarios.

At the event, Dr. Su Jun, Vice President of Chery Automobile Co., Ltd., explained the thinking behind the V25 through three principles: restraint, capability and freedom.

The design retains the V-Series' recognizable proportions and signature styling rather than following short-term trends. Its i-SWIFT Agile Handling Platform, Golden REEV powertrain and i-AWD system support a variety of driving conditions, from urban roads to more challenging terrain.

The V25 also leaves room for personalization, with more than 20 ecosystem interfaces. Other features include a 1.8-ton towing capacity, 6 kW vehicle-to-load (V2L) capability, 66.4% space efficiency, 41 storage spaces and a body made of 80% high-strength steel.

Together, the V23, V25 and V27 show how Future Classic Design can take different forms across the V-Series, combining a recognizable design identity with modern technology and opportunities for personal expression.

Three Officially Customized Models Showcase Different Personalities

Customization is a key highlight of the summit, with three officially customized V-Series models presented alongside 20 customized vehicles developed with users and partners.

Each of the three officially customized models reflects a different interest and lifestyle. The V23 Forge brings urban individuality to life with a muscular widebody stance and gloss-black accents, while retaining the V23's playful character. The V25 Game Changer celebrates the freedom to play, combining the V25's classic toughness with gaming-inspired details. The V27 Sun Roam draws inspiration from 1980s off-road vehicles and vintage cameras, pairing rugged proportions with carefully crafted details.

The three models are planned for introduction in global markets by early 2027, through KD production or dealer-installed packages, subject to local regulations and market conditions. Beyond the official builds, the 20 customized vehicles on display demonstrate how users and partners bring their own ideas to the V-Series. Visitors can explore different styles, learn about customization details and exchange ideas with the teams behind the vehicles.

Customization is already an important part of the iCAUR user experience. According to the brand, 50% of its users worldwide customize their vehicles. Their choices and ideas also provide inspiration for the brand's future products and customization offerings.

Looking ahead, iCAUR plans to introduce dedicated customization spaces in its showrooms, giving customers more opportunities to explore personalization options. The brand also plans to present a customized classic vehicle alongside new models at future model launches, offering inspiration for different ways to make an iCAUR their own.

The brand is continuing to expand its customized vehicle lineup, develop accessories suited to local markets and establish quality and safety validation mechanisms for customization offerings. These efforts aim to make customization more accessible while safeguarding quality and safety.

Connecting Vehicles with Lifestyle Experiences

The iCAUR brand showroom brings together vehicle customization, classic lifestyle elements, and user co-creation, offering visitors a broader view of the brand beyond its vehicles.

Body accessories, outdoor equipment and lifestyle products demonstrate how the vehicle can connect with different interests and everyday activities. Music, travel, surfing and cycling elements reflect the varied ways users explore their interests and express their individuality.

The summit also includes a smart factory tour, giving participants a closer look at iCAUR's manufacturing processes and quality management. During the event, the V-Series multi-scenario test-drive activities will give participants the opportunity to experience the V25 and V27 across different road conditions, including wavy roads, mud, uneven terrain, S-curves and other driving challenges. Activities involving smart ecosystem partner AiMOGA and green community initiatives are also scheduled as part of the five-day program.

Together, these experiences allow users and partners to explore the vehicles, understand the brand's design approach and see how iCAUR connects its products with different lifestyles and interests.

From Official User Clubs to Global Club Connect

For iCAUR, the relationship with users continues well beyond vehicle delivery. The brand has established official user clubs in nine countries, bringing owners together to share experiences and connect through common interests.

In 2027, iCAUR plans to expand this approach through its global Club Connect initiative, bringing together more users across markets, encouraging the exchange of ideas, and using user feedback to inform future products and experiences.

The summit also marks the introduction of iCAUR's first group of Brand Ambassadors. These users are recognized for their creativity, passion, and contributions to the brand. Through Club Connect, iCAUR plans to continue selecting ambassadors who can share their experiences, contribute to brand activities, and inspire other users in their markets.

User participation also extends to customization. Ideas from users may inspire future officially customized models for global markets, creating further opportunities for users to contribute to how iCAUR products evolve.

As the brand continues its international expansion, iCAUR aims to reach more than 70 markets by 2027. Alongside market development, it will continue working with local partners to strengthen sales and service networks and to develop user engagement in different regions.

The 2026 iCAUR International User Summit brings these priorities together through iCAUR's vehicles, customized builds, hands-on experiences, and growing network of user clubs and Brand Ambassadors.

Guided by "Classic Never Fades" and "Make It Yours," iCAUR continues to develop its Future Classic Design philosophy while giving users more opportunities to express their individuality and contribute to the brand. For iCAUR, delivery is not the end of the story, but the starting point for what users can make of their iCAUR.

About iCAUR

Chery Group's iCAUR is a new energy automotive brand driven by Future Classic Design and technology. Guided by its design philosophy, iCAUR combines classic design elements with modern aesthetics and technology to develop distinctive vehicles for urban mobility and outdoor exploration. With a focus on product innovation and customization, iCAUR offers diverse vehicle choices and personalization options, extending its brand experience through user services and a growing range of user engagements initiatives.

iCAUR's product portfolio is supported by technologies including i-AWD intelligent electric all-wheel drive and the REEV Golden Range Extender, delivering performance and capability for a range of driving conditions. With a growing presence in more than 40 markets worldwide, iCAUR continues to expand its international business and user engagements, guided by its brand belief: Classic Never Fades.

Copyright 2026 GlobeNewswire, Inc.

Kolaborasi ini bertujuan untuk meningkatkan perencanaan uji klinis dan memperluas akses pasien ke penelitian yang sesuai dengan biomarker mereka di Australia

Sorotan

*Kolaborasi ini bertujuan untuk mempercepat penelitian onkologi presisi di Australia

*Menggabungkan pengalaman Fortrea dalam uji klinis onkologi dengan program Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) milik Omico

*Bersama-sama, Fortrea dan Omico menawarkan proses pemilihan lokasi penelitian klinis yang lebih efisien serta akses yang lebih cepat bagi pasien dengan menghubungkan mereka ke uji klinis yang relevan berdasarkan biomarker

DURHAM, North Carolina dan SYDNEY, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) ("Perusahaan"), organisasi penelitian berbasis kontrak ("CRO") global terkemuka, dan Omico, organisasi terkemuka di Australia dalam skrining onkologi presisi dan pencocokan pasien dengan uji klinis, hari ini mengumumkan kolaborasi untuk mempercepat penelitian onkologi presisi dengan membantu menghubungkan pasien kanker ke uji klinis yang sesuai dengan biomarker mereka.

Kolaborasi ini menggabungkan jaringan onkologi presisi Omico dengan pengalaman ilmiah dan uji klinis Fortrea. Kerja sama ini bertujuan untuk meningkatkan perencanaan penelitian, pemilihan lokasi penelitian, dan perekrutan pasien guna memperluas akses ke penelitian onkologi berbasis biomarker secara global.

Melalui inisiatif ini, Omico akan mendukung kebutuhan klien Fortrea dalam pengembangan obat onkologi dengan menyediakan akses ke informasi populasi pasien, termasuk profil genomik, kemampuan pencocokan pasien dengan uji klinis, data onkologi dunia nyata, serta jalur rujukan pasien di Australia. Negara ini merupakan salah satu lokasi penting untuk kegiatan penelitian klinis onkologi, baik pada fase awal maupun fase akhir.

Kolaborasi ini akan menggabungkan pengalaman Fortrea dalam pengembangan obat onkologi dengan program unggulan Omico, Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT), yang merupakan inisiatif genomik kanker terbesar di Australia. PrOSPeCT dirancang untuk menyediakan pemeriksaan profil molekuler dan membantu mencocokkan pasien dengan uji klinis berbasis biomarker serta terapi bertarget.

"Melalui kolaborasi kami dengan Omico, kami berupaya menjangkau pasien yang tepat untuk penelitian yang sesuai secepat mungkin," ujar Oren Cohen, M.D., Chief Medical Officer di Fortrea. "Pengembangan onkologi modern menuntut tingkat presisi yang semakin tinggi untuk mencocokkan jenis kanker tertentu dengan terapi yang paling berpotensi memberikan manfaat bagi pasien, dan melakukannya secepat mungkin. Kerja sama kami dengan Omico meningkatkan kemampuan kami untuk lebih cepat mengidentifikasi pasien yang tepat bagi penelitian berbasis biomarker di Australia serta membantu memajukan pengobatan presisi bagi penderita kanker."

Omico telah membangun salah satu ekosistem onkologi presisi terluas di Australia yang menggabungkan pemeriksaan profil molekuler, bukti dunia nyata, program penelitian kohort, serta jaringan peneliti dan lokasi penelitian klinis di seluruh Australia. Omico melaporkan bahwa basis data klinis dan genomiknya mencakup lebih dari 23.000 pasien yang telah memberikan persetujuan. Selain itu, Omico telah menerima rujukan dari lebih dari 1.600 tenaga medis di seluruh Australia.

"Australia berada di posisi yang tepat untuk mendukung uji klinis berbasis biomarker secara global berkat infrastruktur penelitian onkologi presisi nasional, keahlian, dan jaringan yang telah dibangun Omico," ujar Profesor David Thomas, Chief Science and Strategy Officer di Omico. "Dengan menggabungkan kemampuan kami dalam pengelolaan data dan pencocokan pasien dengan uji klinis di tingkat nasional serta keahlian Fortrea dalam pengembangan klinis global. Dengan begitu, kami dapat membantu sponsor internasional mengidentifikasi populasi pasien yang relevan, merencanakan uji klinis secara lebih efektif, dan mendukung perekrutan pasien yang tepat sasaran."

Keahlian Fortrea di bidang onkologi ditopang oleh ribuan tenaga profesional operasional dan didukung oleh lebih dari 50 dokter spesialis onkologi yang tergabung dalam jajaran stafnya. Kolaborasi ini berlangsung di tengah perkembangan obat onkologi modern yang semakin mendorong fokus pada pengobatan presisi, pengembangan obat berbasis biomarker, dan identifikasi pasien secara tepat sasaran. Melalui kerja sama ini, Fortrea dan Omico dapat meningkatkan efisiensi pemilihan lokasi penelitian serta kemampuan untuk mencocokkan pasien dengan penelitian yang sesuai berdasarkan data genomik unik mereka. Hal ini memungkinkan lebih banyak pasien di Australia untuk berpartisipasi dalam penelitian yang disesuaikan dengan kondisi kesehatan masing-masing.

Tentang Fortrea

Fortrea (Nasdaq: FTRE) adalah penyedia solusi pengembangan klinis global terkemuka untuk industri ilmu hayati. Kami bermitra dengan perusahaan biofarmasi, bioteknologi, alat medis, dan diagnostik besar dan sedang berkembang untuk mendorong inovasi layanan kesehatan yang mempercepat terapi yang mengubah hidup pasien. Fortrea menyediakan manajemen uji klinis fase I-IV, farmakologi klinis, dan layanan konsultasi. Solusi Fortrea memanfaatkan pengalaman selama tiga dekade yang mencakup lebih dari 20 area terapeutik, antusiasme terhadap ketelitian ilmiah, wawasan luar biasa, serta jaringan situs peneliti yang kuat. Tim kami yang berbakat dan beragam, yang bekerja di sekitar 100 negara, memiliki skala yang memadai untuk memberikan solusi yang terfokus dan tangkas kepada klien di seluruh dunia. Pelajari lebih lanjut bagaimana Fortrea menyederhanakan proses pengembangan obat di Fortrea.com dan ikuti kami di LinkedIn, X, dan Bluesky.

Tentang Omico

Omico adalah organisasi penelitian nasional independen dan nirlaba yang mengubah cara kita melawan kanker. Kami berupaya meningkatkan hasil pengobatan bagi penderita kanker di Australia dengan menyediakan akses yang setara ke layanan onkologi presisi serta menerapkan kemajuan ilmiah dalam perawatan klinis dan penelitian. Kami juga menghasilkan bukti yang diperlukan sebagai dasar penyusunan kebijakan kesehatan dan reformasi sistem kesehatan. Melalui kerja sama dengan lembaga kanker terkemuka, peneliti, klinisi, mitra industri, kelompok advokasi, dan pemerintah di Australia, kami mempercepat pemeriksaan profil molekuler, uji klinis berbasis biomarker, pengelolaan risiko kanker yang dipersonalisasi, serta bukti dunia nyata.

Tentang PrOSPeCT

PrOSPeCT merupakan inisiatif onkologi presisi terbesar di Australia. Program ini diselenggarakan oleh Omico bersama jaringan nasional mitra layanan kesehatan, penelitian, dan industri. Program ini memberikan akses kepada warga Australia yang memenuhi syarat untuk menjalani pemeriksaan profil molekuler serta pencocokan dengan uji klinis dan terapi berbasis biomarker (tanpa biaya bagi pasien). Selain itu, program ini menghasilkan data klinis, genomik, pengobatan, dan hasil pengobatan untuk memajukan penelitian, meningkatkan kualitas perawatan kanker, serta menjadi dasar penyusunan kebijakan kesehatan di masa depan.

Kontak Fortrea:

Galen Wilson (Media) - 703-298-0802, media@fortrea.com

Kate Dillon (Media) - 646-818-9115, kdillon@prosek.com

Tracy Krumme (Investor) - 984-385-6707, Tracy.Krumme@fortrea.com

Kontak Omico :

Kym Bramich (Komunikasi) +61 414 795 087, k.bramich@omico.org.au

Copyright 2026 GlobeNewswire, Inc.

Featuring AI pioneer Dr. Kevin Knight

Guangzhou, China, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Tec-Do today hosted Technology Growth Conference 2026 (TGC 2026) in Guangzhou under the theme "AI is Profitable." Featuring AI pioneer Dr. Kevin Knight and speakers from OpenAI, Google, Alibaba, ByteDance and Tencent, the conference explored how AI can deliver measurable business value.

At the event, Tec-Do launched Navos Pro, which the company describes as the industry's first Pro-Agent. Built around three attributes-Professional, Proactive and Profitable-the product advances Tec-Do's results-driven approach to AI for Work.

From AI Capabilities to Business Results

In his opening keynote, "From Language to Action: The Next Leap in AI," Dr. Knight drew on his academic and industry experience to identify AI for Work as a major direction for AI applications.

Shuhao Li, Founder and CEO of Tec-Do, outlined a multitrillion-dollar opportunity across three areas of enterprise spending: marketing and sales, coding and product development, and management. These correspond to AI for Growth, AI for Innovation and AI for Administration. Within this framework, Li positioned Navos Pro as a leading contender in AI for Growth.

"We focus exclusively on results-driven AI for Work," Li said.

Designed for cross-border ecommerce, international trade, marketing and business analysis, Navos Pro combines:

Professional: Builds a private knowledge base from a brand's website and retains business context to produce outputs aligned with its commercial objectives.

Proactive:Monitors data around the clock to identify opportunities and recommend actions, while people retain decision-making authority.

Profitable: Connects strategy, creative development and advertising execution to measurable outcomes, including gross merchandise value (GMV) and return on investment (ROI).

These capabilities are supported by specialized 32B, 27B and 5B parameter models, industry knowledge, more than 70 MCP integrations and over 100 skills. According to Tec-Do, the platform monitors more than 1 billion data points daily. A Learning Loop connects results with strategy optimization, while Navos RSI uses agentic reinforcement learning to improve its Agent Harness.

The architecture supports deployment across markets, channels and industries. The product portfolio includes Navos Lite and Navos Pro, covering the end-to-end international marketing workflow.

From Responding to Initiating Work

Li described the evolution from Chatbots to Copilots to Pro-Agents as a shift in who initiates work: from responding to requests, to assisting execution, to proactively identifying opportunities and delivering growth. He argued that the AI industry is moving from providing capabilities to proving business value.

Drawing on its experience serving hundreds of thousands of brands expanding internationally, Tec-Do is extending this approach through partnerships. The company said it became one of the first global technology partners for ChatGPT Ads in July 2026, helping brands raise ROI to 2.5 times previous levels. In August, it partnered with Tencent WorkBuddy to apply AI capabilities to international advertising.

Li said AI for Growth is the first step, with plans to extend Tec-Do's capabilities into AI for Innovation and AI for Administration.

Advancing AI Commercialization

Lorry Destainville, Monetization Partnerships at OpenAI, shared perspectives on ChatGPT's commercialization. He said ChatGPT reaches 1.2 billion users weekly and that OpenAI is exploring Sponsored Agents and Visual Ads. He also thanked Tec-Do for collaborating on practical, measurable AI growth tools for brands.

Three panels, moderated by Maeve Zhang, Vice President of Branding and Public Relations at Tec-Do, examined AI's impact on business, international expansion and ecosystem collaboration, bringing together technology providers, entrepreneurs and investors.

The conference concluded with Eileen Nie, Founding Partner and Head of Ecosystem Incubation and Strategic Investment at Tec-Do, announcing the Pro-Agent Global Challenge. The initiative invites entrepreneurs worldwide to submit projects in agent architecture, AI marketing, AI content gateways and computing infrastructure, offering access to capital, industry resources and global growth channels.

About Tec-Do

Founded in 2017, Tec-Do is a leading AI marketing company delivering results-centric marketing solutions for global business growth. Powered by Tec-Chi multi-modal large language models (MLLMs) and Marketing Multi-Agent Platform Navos, the company delivers end-to-end marketing solutions through a suite of AI-native, performance-driven products.

These products restructure and autonomize mission-critical marketing processes-including market intelligence, content generation, campaign delivery, and performance optimization-across global media channels. In 2025, Tec-Do served over 100,000 advertisers, representing a diversified customer base that spans e-commerce, gaming, entertainment, and local commerce.

Copyright 2026 GlobeNewswire, Inc.

A statue tells the story of "Half a Quilt" in Shazhou, Hunan Province, central China. /VCG

BEIJING, Oct. 23, 2026 (GLOBE NEWSWIRE) -- CGTN menerbitkan sebuah artikel untuk memperingati 90 tahun kemenangan Tentara Merah dalam Mars Panjang. Berangkat dari kisah "Separuh Selimut", artikel tersebut menyoroti pesan Presiden Xi Jinping agar semangat Mars Panjang terus dihidupkan dalam perjalanan modernisasi Tiongkok.

Artikel tersebut juga menggali pandangan para pengamat internasional mengenai pelajaran yang dapat dipetik negara-negara Selatan Global dari pengalaman pembangunan Tiongkok.

Pada musim dingin 1934, di tengah perjalanan Mars Panjang, tiga prajurit perempuan Tentara Merah tiba di rumah Xu Jiexiu, seorang warga miskin di Desa Shazhou, Provinsi Hunan. Melihat keluarga Xu hampir tak punya apa-apa untuk menghangatkan diri, ketiga prajurit itu memotong satu-satunya selimut mereka menjadi dua dan meninggalkan separuhnya untuk Xu sebelum melanjutkan perjalanan.

Kebaikan tersebut kemudian dikenal sebagai kisah "Separuh Selimut," sebuah simbol abadi tentang ikatan antara Partai Komunis Tiongkok (PKT) dan rakyat.

Presiden Tiongkok Xi Jinping kembali mengangkat kisah tersebut pada hari Kamis dalam acara peringatan 90 tahun kemenangan Mars Panjang Tentara Merah.

"Hanya dengan mengingat sejarah, kita dapat menciptakan masa depan yang lebih cerah," ujar Xi. Xi menegaskan bahwa dukungan rakyat menjadi kunci kemenangan Mars Panjang, sekaligus menyerukan agar Tiongkok terus menorehkan pencapaian baru dalam perjalanannya menuju modernisasi.

Dari separuh selimut menuju kehidupan yang lebih baik

Saat mengunjungi balai pameran bertema "Separuh Selimut" pada September 2020, Xi menyerukan agar partai senantiasa bersatu dengan rakyat dalam menempuh Mars Panjang di era baru.

Kini, komitmen tersebut tercermin dalam berbagai upaya untuk meningkatkan taraf hidup rakyat. Desa tersebut memberikan tunjangan bulanan bagi warga berusia 60 tahun ke atas dan menanggung separuh iuran asuransi kesehatan dasar warganya. Selain itu, program layanan ramah anak juga telah diperluas hingga menjangkau sembilan desa di sekitarnya.

Bagi keturunan Xu, perubahan tersebut benar-benar terasa nyata. Cucunya, Zhu Xiaohong, dulu pernah hidup dalam kemiskinan. Berkat dukungan otoritas PKT setempat, ia mengikuti pelatihan kuliner lalu membuka sebuah restoran.

"Dulu Tentara Merah memberi kami separuh selimut; kini Partai tersebut memberi kami kehidupan yang bahagia," tutur Zhu.

Josef Gregory Mahoney, profesor politik dan hubungan internasional di East China Normal University, berbicara kepada CGTN tentang makna Mars Panjang. Menurutnya, pelajaran abadi dari peristiwa tersebut adalah bahwa kepercayaan publik dibangun dengan memenuhi kebutuhan masyarakat serta menanggung kesulitan bersama-sama dan berbagi pencapaian bersama-sama. Kini, upaya pengentasan kemiskinan dan revitalisasi perdesaan pun bergantung pada hal yang sama, yakni memastikan rakyat merasakan manfaat nyata dalam kehidupan mereka.

Seperti yang ditegaskan Xi pada hari Kamis, keteguhan memegang cita-cita dan tujuan Partai serta kedekatan dengan rakyat merupakan kunci untuk meraih pencapaian-pencapaian baru.

Mars Panjang Baru

Kini, Shazhou merintis jalannya sendiri dalam Mars Panjang baru dengan mengubah warisan revolusioner dan sumber daya ekologisnya menjadi peluang bagi pembangunan berkelanjutan dan kemakmuran bersama.

Desa tersebut telah memugar situs-situs bersejarah revolusi dan mengembangkan wisata merah. Di saat yang sama, kualitas lingkungan tempat tinggal warga juga terus diperbaiki melalui pengelolaan sungai, pengolahan air limbah, dan pengumpulan sampah. Wilayah di sekitarnya juga mendorong budi daya buah-buahan khas serta memadukan pertanian dengan pariwisata. Langkah ini membuka peluang baru bagi usaha lokal dan lapangan kerja, sekaligus menopang pembangunan perdesaan yang lebih berkelanjutan.

Hasilnya pun tercermin dalam statistik setempat. Shazhou resmi keluar dari daftar desa miskin pada tahun 2018. Pada tahun 2025, pendapatan bersih per kapita tahunan warga desa telah meningkat dari kurang dari 4.000 yuan (sekitar $634) pada tahun 2012 menjadi lebih dari 25.000 yuan. Sementara itu, pendapatan kolektif desa yang semula nyaris nol kini telah melampaui 1 juta yuan.

Pakar asal Brasil, Rafael Henrique Zerbeto, yang turut serta dalam program napak tilas Mars Panjang, mengatakan bahwa mengutamakan kepentingan rakyat tetap menjadi hal yang sangat penting bagi pembangunan Tiongkok. Mulai pelestarian warisan revolusioner hingga pengembangan industri khas daerah yang meningkatkan pendapatan warga, ia menyaksikan bagaimana Tiongkok berhasil mengubah semangat Mars Panjang menjadi kekuatan pendorong pembangunan berkualitas tinggi.

Survei terbaru CGTN terhadap 12.000 responden di 41 negara menunjukkan bahwa 63,9% responden global melihat adanya kaitan erat antara kepemimpinan PKT dan berbagai pencapaian pembangunan Tiongkok. Di kalangan responden dari negara-negara Selatan Global, angka tersebut bahkan mencapai 71,4%.

Bagi Mahoney, Mars Panjang juga memberikan pelajaran bagi negara-negara Selatan Global: jalur pembangunan harus disesuaikan dengan kondisi setempat, sementara tantangan bersama menuntut kerja sama internasional. Secara lebih luas, Mars Panjang mengajarkan bahwa kemajuan yang berkelanjutan berawal dari kemampuan suatu negara untuk bertumpu pada kekuatannya sendiri, sekaligus bekerja sama dengan pihak lain demi mencapai tujuan bersama.

Sebagaimana disampaikan Xi dalam pidato peringatannya, semangat Mars Panjang tetap menjadi "harta yang tak ternilai sekaligus kekuatan pendorong yang besar, yang menginspirasi kita untuk menaklukkan berbagai kesulitan dan terus melangkah maju dengan penuh keberanian."

Copyright 2026 GlobeNewswire, Inc.

Miami, Oct. 23, 2026 (GLOBE NEWSWIRE) --

The news in brief:

Muck Rack was named as a Leader in the 2026 Gartner Magic Quadrant for PR and Media Monitoring Tools, the first Magic Quadrant Gartner has published for this market.

It was Muck Rack's first evaluation for the report.

Muck Rack is a single platform for communications teams that connects journalist research, pitching, press release distribution, monitoring of more than 600,000 global sources, sentiment tracking and AI visibility measurement with Generative Pulse.

Muck Rack has expanded across Europe, with teams in Ireland, Bulgaria and the UK.

Muck Rack, the AI communications platform, today announced it has been named as a Leader in the 2026 Gartner Magic Quadrant for PR and Media Monitoring Tools, the first Magic Quadrant Gartner has published for this market.

Muck Rack views the report as a milestone for the communications profession. Muck Rack believes earned media and communications technology is now a category that enterprise buyers procure with the same rigor they apply to CRM or marketing automation.

"We're honored to be named as a Leader the first time we were evaluated, but the bigger story is that PR technology now has its own Magic Quadrant," said Greg Galant, cofounder and CEO of Muck Rack. "For every communications team that's had to make the case for earned media, narrative and reputation, that's validation. Enterprises now invest in communications seriously, and they expect the tools behind it to hold up to serious scrutiny."

Muck Rack believes that scrutiny reflects how much the job has changed. Communications leaders now pick up signals from news, social platforms, podcasts, newsletters and generative AI models. In Muck Rack's view, PR professionals need more than monitoring to understand the narrative, act quickly and prove their value to the business.

Muck Rack was built from the start as a single platform for communications teams, connecting the entire PR workflow in one system of record. Teams can find journalists, monitor more than 600,000 global sources, track sentiment, pitch and distribute news, and measure how their brand appears in AI-generated answers with Generative Pulse. All of it runs on the same intelligence engine and the same verified media data, maintained by Muck Rack's editorial team and by journalists themselves. AI takes on the heavy lifting of research, filtering, summarization and targeting, and each part of the platform strengthens the next: monitoring sharpens outreach, outreach is tied to the coverage it produces, and reporting shows teams what to refine next.

The release also added agentic coverage analysis, AI summaries, multi-subject monitoring, expanded Curation Engine capabilities, flexible analytics, Global Tags, broader broadcast and licensed content monitoring, redesigned Coverage Reports and an MCP integration. Together, these updates cut the manual work of organizing and analyzing coverage. The company has also expanded across Europe, with a support team in Ireland, an insights operation in Bulgaria, and sales and customer success in the UK.

Check out Muck Rack by requesting a demo.

Gartner Report, Magic Quadrant for PR and Media Monitoring Tools, By Amber Boyes, Paul Swiergosz, etc., October 2026. 

GARTNER and MAGIC QUADRANT are the trademark of Gartner, Inc. and/or its affiliates.

Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner's business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose. 

About Muck Rack

Muck Rack is the AI communications platform where trusted data, human expertise, and embedded intelligence come together to drive clarity, speed and impact. Thousands of companies turn to Muck Rack to make sense of the media conversation around them and understand how their brand shows up in the news and in AI-generated answers.

Muck Rack combines global media monitoring, Generative Engine Optimization (GEO) insights, social listening, trusted media data, AI automation, and analyst advisory to help organizations manage reputation, act quickly, and prove their impact across the PR workflow. Thousands of journalists also use Muck Rack's free tools to showcase their work and analyze the news. Learn more at muckrack.com.

We're Hiring!

Copyright 2026 GlobeNewswire, Inc.

*WeRide was named among WICV 2026's "Top 10 Automotive AI Application Cases of 2026" for its Physical AI flywheel powered by GENESIS and WITT.

*Founder and CEO Dr. Tony Han shared WeRide's approach to applying L4 autonomous driving technology to L2 advanced driver-assistance systems, emphasizing intelligence density and safety.

*WeRide continues to expand real-world deployment across L2 to L4, with operations in more than 60 cities across 13 countries and an L4 fleet of approximately 3,600 vehicles.

BEIJING, Oct. 23, 2026 (GLOBE NEWSWIRE) -- WeRide (NASDAQ: WRD, HKEX: 0800), a global leader in autonomous driving technology, has been named among the "Top 10 Automotive AI Application Cases of 2026" at the 2026 World Intelligent Connected Vehicles Conference (WICV). The recognition highlights WeRide's innovative Physical AI flywheel powered by WeRide GENESIS and WeRide WITT, demonstrating how the company is translating cutting-edge AI technologies into large-scale commercial applications.

The selected case of WeRide's Physical AI flywheel, highlights the practical application of the collaborative application of cutting-edge AI technologies in autonomous driving development. At its core, the flywheel brings together WeRide GENESIS, WeRide's proprietary general-purpose simulation model, and WeRide WITT, WeRide's Physical AI Cognitive Foundation Model.

WeRide WITT extracts and validates physical facts from real-world road data, while WeRide GENESIS uses these insights to generate high-fidelity simulation scenarios that adhere to real-world physical laws, strengthening training in complex driving scenarios and long-tail situations. Together, the two models empower vehicle-side models, improve development efficiency and adaptability to complex scenarios, and support the deployment of autonomous driving technology across cities and vehicle platforms.

Focusing on the path to scaled production of autonomous driving, Dr. Tony Han, Founder and CEO of WeRide, delivered a keynote titled "The Critical Leap Toward Scaled Deployment of Autonomous Driving" at the conference's Key Technology Forum, sharing WeRide's experience in applying L4 expertise to L2 advanced driver-assistance systems (ADAS).

Dr. Han highlighted "intelligence density" as a key metric for evaluating ADAS solutions: how much intelligence each TOPS of computing power can deliver. The goal is to achieve a higher level of intelligent driving with limited computing resources. He also emphasized that investing in safety is essential to earning user trust and building long-term brand value. As the technology advances and its applications expand, safety must remain a priority at every stage, protecting not only passengers inside the vehicle but also every road user outside it.

WICV 2026 was held in Yizhuang, Beijing, from October 21 to 23, and was co-hosted by China's Ministry of Industry and Information Technology, Ministry of Transport, and the People's Government of Beijing Municipality. This year's conference was themed "Pooling Wisdom, Boundless Connectivity: Advancing Steadily Towards a New Era of Automated Driving". The conference has been held annually since 2018 and serves as a major industry event for intelligent connected vehicles, as well as an important platform for policy development and international cooperation.

WeRide's autonomous driving technologies were also showcased in real-world applications during the conference. During WICV 2026, WeRide deployed more than a dozen Robotaxis and Robobuses, providing autonomous ride experiences and shuttle services for attendees. The nearly 7-kilometer Robotaxi experience route started and ended at the main venue, while Robobuses provided shuttle services connecting conference venues and visitor destinations, including Yonghui Building, BAIC BluePark, Rocket Street, and Robot World.

Today, WeRide has commercialized its full-stack autonomous driving technologies spanning L2 to L4, with operations spanning more than 60 cities across 13 countries worldwide. Its L4 autonomous driving fleet comprises approximately 3,600 vehicles, supported by extensive operating experience across different cities and real-world use cases.

WeRide's autonomous passenger vehicles are already operating publicly in major global cities, including Guangzhou, Beijing, Abu Dhabi, Dubai, Singapore, Riyadh, and Zurich. Through global mobility platforms such as Uber and Grab, as well as local partners including SBB, ioki and TXAI, WeRide is integrating autonomous driving into more urban transportation networks and will soon launch services in additional markets including Spain and Denmark.

WeRide's L4 autonomous driving technology is also empowering mass-produced passenger vehicles through shared technology architecture. WRD 3.0, WeRide's one-stage end-to-end L2++ ADAS solution, has been deployed on models including the Chery Exeed Sterra, GAC AION N60, AION i60, and GAC Trumpchi Y7. To date, WRD 3.0 has secured production design wins across more than 30 vehicle models, bringing advanced driving technologies to a broader consumer base.

As the intelligent connected vehicle industry enters a new phase of development, WeRide will continue to advance Physical AI innovation and promote technological synergies across L2 to L4. Working with global industry partners, WeRide will expand the real-world application of its technologies at scale, translating technological progress into safer and more reliable mobility experiences.

About WeRide

WeRide is a global leader and a first mover in the autonomous driving industry, as well as the first publicly traded Robotaxi company. Our autonomous vehicles have been deployed in over 60 cities across 13 countries. We are also the first and only technology company whose products have received autonomous driving permits in nine markets: China, the UAE, Singapore, France, Switzerland, Saudi Arabia, Belgium, Spain, and the US. Empowered by the smart, versatile, cost-effective, and highly adaptable WeRide One platform, WeRide provides autonomous driving products and services from L2 to L4, addressing transportation needs in the mobility, logistics, and sanitation industries. WeRide was named to Fortune's Change the World lists in 2023, 2025, and 2026, and to the Fortune Future 50 list in 2025.

Safe Harbor Statement

This press release contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "likely to," and similar statements.

Statements that are not historical facts, including statements about WeRide's beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in WeRide's filings with the U.S. Securities and Exchange Commission and announcements on the website of the Hong Kong Stock Exchange.

All information provided in this press release is as of the date of this press release. WeRide does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Copyright  2026 GlobeNewswire, Inc.

HONG KONG SAR - Media OutReach Newswire - 23 October 2026 - Louis Vuitton unveils a new hoarding in Hong Kong following the iconic ones on the Champs-?lys?es in Paris in September 2023, in New York in November 2024, and in Shanghai in June 2025 .

Louis Vuitton unveils in October 2026 a spectacular hoarding inspired by one of the House's most emblematic themes: the Art of Travel. Throughout the refurbishment, the fa?ade is transformed into a grand train station, evoking the romance and golden age of travel. In celebration of the 130rh anniversary of the Monogram, this reimagined station will also be decorated with the House's distinctive Monogram motif.

Conceived as a tribute to the House's enduring fascination with travel, and as a nod to Hong Kong's comprehensive transportation history, the installation brings together heritage, imagination and architectural presence. In keeping with Louis Vuitton's commitment to more mindful creation, all materials used in the construction of the fa?ade will later be reused or recycled. Designed to capture the city's vibrant energy, this striking installation will be established as a new monument for all.

About Louis Vuitton

Since 1854, Louis Vuitton has brought unique designs to the world, combining innovation with style, always aiming the finest quality. Today, the House remains faithful to the spirit of its founder, Louis Vuitton, who invented a genuine "Art of Travel" through luggage, bags and accessories which were as creative as they were elegant and practical.

Since then, audacity has shaped the story of Louis Vuitton. Faithful to its heritage, Louis Vuitton has opened its doors to architects, artists and designers across the years, all the while developing disciplines such as ready-to-wear, shoes, accessories, watches, jewellery, beauty, and fragrance. These carefully created products are testament to Louis Vuitton's commitment to fine craftsmanship.

For further information: www.louisvuitton.com

The issuer is solely responsible for the content of this announcement.

Hashtags: #LouisVuitton

*Zymeworks to receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial, with potential for up to $718 million in additional development, commercial and sales-based milestones 

*Zymeworks also eligible to receive tiered high-single-digit to mid-teen royalties on global net sales protected by patents extending into 2040's

*Zymeworks will conduct the Phase 1a monotherapy clinical trial of ZW209 in collaboration with Roche 

*U.S. FDA IND clearance received with additional global regulatory applications planned to support the opening of clinical study sites outside the U.S.

*Transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976

*Conference call with Zymeworks management on October 27 at 8:30 am Eastern Time (ET)

VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that it has entered into a global license and collaboration agreement with Roche for the research, development and commercialization of ZW209, a T cell engager targeting DLL3.

Under the agreement, Zymeworks is eligible to receive an upfront payment of $55 million, a $40 million payment upon initiation of the Phase 1b trial, and additional development, commercial and sales-based milestone payments of up to $718 million, and tiered high single digit to mid-teen royalties on future net sales of any approved medicines resulting from the collaboration.

The transaction remains subject to the expiration or termination of the applicable waiting period under the HSR Act, as well as the satisfaction of other customary closing conditions and, where applicable, receipt of other required regulatory approvals.

Zymeworks will conduct the Phase 1a monotherapy trial of ZW209 in collaboration with Roche, bringing together Zymeworks' expertise in multispecific antibody therapeutics with Roche's global capabilities in the research, development, manufacturing and commercialization of cancer medicines. Roche will fund the Phase 1a trial and be responsible for subsequent global development and commercialization of ZW209. Under the agreement, Roche will have the exclusive right to develop and commercialize ZW209 globally.

"This collaboration allows us to continue advancing ZW209 through its initial clinical development while leveraging Roche's complementary capabilities to accelerate and expand its development across indications and treatment settings. The agreement also reflects our broader strategy of generating innovative programs through our R&D engine and partnering selected assets in ways that share development risk while preserving meaningful participation in their future success," said Adam Schayowitz, Ph.D., MBA, Executive Vice President and Head of R&D at Zymeworks.

"ZW209 represents an innovative approach that complements our ongoing efforts to develop new treatment options for people living with lung cancer," said Boris L. Zaitra, Head of Corporate Business Development at Roche. "We look forward to collaborating with Zymeworks to fully explore its therapeutic potential."

The collaboration is part of Zymeworks' broader strategic initiative to advance differentiated therapeutic candidates internally while selectively partnering programs where complementary capabilities can accelerate development, expand potential and share development risk. Beyond ZW209, Zymeworks has an extensive portfolio of research programs of multispecific T cell engagers against targets in solid tumors, hematological tumors, and AIID.

Investor Call Details

Zymeworks invites investors and the general public to view and listen to a live webcast of its conference call with investment analysts at 8:30 am ET on October 27, 2026.

Dial-in details and webcast link are available on Zymeworks' website at https://ir.zymeworks.com/events-and-presentations. A webcast replay of the call will be available on the Zymeworks website within 24 hours following the conclusion of the live call and will be archived for a limited period.

About ZW209

ZW209 is a novel trispecific T cell engager (TriTCE), developed to target DLL3-expressing tumor cells while simultaneously engaging T cells via binding to CD3 and CD28. Optimally configured using Zymeworks' novel TriTCE Co-Stim and clinically validated Azymetric and EFECT platforms, ZW209 is designed to enhance patient anti-tumor T cell responses through CD28 co-stimulation.

By leveraging obligate cis-T cell binding and conditional CD28 engagement, ZW209 is structured to prevent unintended T cell activation, while enabling tumor-targeted cytotoxicity. Preclinically ZW209 has demonstrated differentiated long-term cytotoxicity in vitro, with enhanced T cell proliferation and survival, offering significant potential to increase durability of responses in DLL3-expressing cancers.

With U.S. Food and Drug Administration Investigational New Drug clearance received, a Phase 1, open-label, multicenter, global study investigating ZW209 has been initiated to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity. The study will enroll adult participants with select advanced solid tumors, including small cell lung cancer and other DLL3 expressing neuroendocrine tumors.

About Zymeworks Inc.

Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. The Company's asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI? (revefenacin), with a differentiated internal research and development engine. Zymeworks' portfolio also includes Ziihera? (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks' proprietary antibody engineering technologies.

Zymeworks is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric? platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. These capabilities, together with Zymeworks' integrated drug development expertise, enable the Company to develop differentiated therapeutics and create value through both internal innovation and strategic partnerships.

For more information about Zymeworks, its portfolio and pipeline, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks' expectations regarding implementation of its long-term strategy to maximize value creation; Zymeworks' and its partners' clinical development of product candidates; potential safety profile and therapeutic effects of product candidates; the commercial potential of technology platforms and product candidates; the anticipated benefits of its collaboration agreements; and other information that is not historical information.

When used herein, words such as "plan", "believe", "expect", "may", "continue", "anticipate", "potential", "will", "on track", "progress", "preserve", "intend", "could", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking.

All forward-looking statements are based upon Zymeworks' current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks' or its partners' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; uncertainties regarding the commercial success of YUPELRI and TRELEGY; Zymeworks may not achieve milestones or receive additional payments or royalties under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks' business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks' behalf; zanidatamab may not be successfully commercialized; Zymeworks' business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented; Zymeworks' evolution of its business strategy may not deliver meaningful stockholder returns; Zymeworks may be unsuccessful in actively managing and/or aggregating revenue-generating assets alongside its active R&D operations; ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks' or its collaborators' product candidates; data providing early validation of our antibody drug conjugate platform and next generation pipeline programs may not be replicated in future studies; Zymeworks' assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new partnerships or strategic collaborations; the inability of Zymeworks to identify and consummate a strategic acquisition; and the factors described under "Risk Factors" in Zymeworks' quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Copyright 2026 GlobeNewswire, Inc.

Membangun fondasi operasional bagi kecerdasan generasi berikutnya di lingkungan hotel

SINGAPURA, Oct. 23, 2026 (GLOBE NEWSWIRE) -- YYForce Inc. (Nasdaq: YFOR) ("YYForce" atau "Perusahaan"), penyedia layanan pengelolaan tenaga kerja dan pengelolaan fasilitas terpadu yang didukung AI, hari ini memaparkan visinya untuk mengembangkan platform terpadu yang menghubungkan keahlian manusia, kecerdasan buatan, robotika, dan sistem bangunan pintar.

Ambisi jangka panjang Perusahaan adalah membangun infrastruktur operasional yang dapat mendukung penerapan kecerdasan super di masa depan dalam sektor perhotelan dan lingkungan binaan, jika kemampuan tersebut telah tersedia.

Platform yang direncanakan ini bertujuan membantu operator hotel mengoordinasikan tenaga kerja, penyediaan layanan, tugas-tugas robot, dan kinerja bangunan melalui lapisan operasional bersama. YYForce bertujuan menghubungkan informasi dari sistem hotel dan sensor IoT dengan alur kerja yang memungkinkan manusia, robot, dan peralatan yang terhubung untuk merespons kebutuhan operasional.

Membangun Infrastruktur Operasional untuk Kecerdasan Super di Masa Depan

Pendekatan yang diusulkan YYForce bertujuan mengintegrasikan penilaian manusia dan keahlian dalam pelayanan, perkiraan dan perencanaan yang dibantu AI, sistem robotika dan humanoid untuk tugas-tugas fisik yang sesuai, serta pemantauan dan pengendalian yang didukung IoT. Prioritas pengembangan mencakup integrasi data, koordinasi tugas, verifikasi hasil, dan pengawasan manusia.

Sebagai contoh, seperti yang dibayangkan, alur kerja yang terhubung berpotensi menggunakan informasi check-out untuk menjadwalkan pembersihan kamar dan mengalokasikan dukungan robot yang sesuai. Selain itu, sistem juga dapat menyesuaikan pencahayaan dan pendinginan kamar dalam batas kenyamanan yang telah disetujui. Data penyelesaian tugas dan umpan balik sensor berpotensi membantu operator memverifikasi kesiapan kamar dan menilai kinerja operasional.

"Ambisi kami adalah memberikan cara praktis bagi AI yang semakin canggih untuk memahami dan mendukung operasional hotel yang sesungguhnya," ujar Mike Fu, Chief Executive Officer YYForce. "Dengan menghubungkan manusia, sistem robotika, dan sistem bangunan, kami ingin mengubah informasi operasional menjadi tindakan yang terkoordinasi dan hasil yang terukur. Seiring waktu, kami yakin infrastruktur ini dapat mendukung penerapan kecerdasan super di masa depan, dengan tetap memastikan adanya kejelasan dalam pembagian wewenang dan tanggung jawab operasional."

Menghubungkan Peningkatan Bangunan Pintar dengan Visi Kecerdasan Super

Sebagai bagian dari arah pengembangan ini, YYForce berencana mengintegrasikan solusi peningkatan kualitas hotel yang mencakup sensor okupansi dan lingkungan, pengendalian pencahayaan, pengaturan suhu, pemantauan peralatan, serta alur kerja pemeliharaan. Tujuannya adalah membantu pengelola properti meningkatkan kenyamanan tamu, mengurangi konsumsi energi yang tidak perlu, serta merespons masalah pada peralatan lebih awal.

Perusahaan berencana mendukung upaya hotel menuju operasional dengan emisi karbon yang lebih rendah melalui pemantauan energi, pengoptimalan operasional, dan pengukuran kinerja. Peningkatan kualitas sistem bangunan pintar saja tidak cukup menjadikan properti berstatus emisi karbon nol bersih. Setiap klaim emisi karbon nol bersih di masa depan harus didukung oleh cakupan emisi yang ditetapkan secara jelas, kinerja yang terverifikasi, serta langkah-langkah yang tepat untuk menangani pasokan energi dan emisi yang tersisa.

Jalur Pengembangan yang Terukur Menuju Penerapan Kecerdasan Super di Masa Depan

Pendekatan pengembangan yang diusulkan YYForce akan dimulai dengan alur kerja yang jelas di sektor perhotelan, dilanjutkan dengan penetapan tolok ukur kinerja dan evaluasi hasil sebelum memperluas otomatisasi. Aspek yang direncanakan untuk dievaluasi meliputi penyelesaian layanan, kesiapan kamar, produktivitas tenaga kerja, penggunaan energi, dan keandalan. Peningkatan akan diuji sebelum diterapkan secara lebih luas, dengan mekanisme eskalasi kepada manusia serta batasan operasional yang disesuaikan dengan setiap penerapan.

Visi kecerdasan super merupakan ambisi strategis jangka panjang. YYForce tidak mengumumkan bahwa perusahaan tersebut telah mengembangkan kecerdasan umum buatan atau kecerdasan super buatan. Fokus jangka pendek perusahaan adalah membangun platform operasional yang terintegrasi. Sementara itu, penggunaan sistem kecerdasan super di masa depan akan bergantung pada kemajuan kemampuan dasar AI serta keberhasilan validasi teknis dan operasional.

Tentang YYForce

YYForce Inc. (Nasdaq: YFOR) adalah penyedia layanan pengelolaan tenaga kerja dan pengelolaan fasilitas terpadu (IFM) yang didukung AI, yang berkantor pusat di Singapura serta beroperasi di Asia dan wilayah lainnya. Melalui bisnis IFM dan teknologi tenaga kerjanya, YYForce menyediakan solusi pengerahan dan pengelolaan tenaga kerja serta layanan fasilitas di berbagai industri jasa.

Platform tenaga kerja Perusahaan, YY Circle, mendukung pengerahan dan pengelolaan tenaga kerja di berbagai sektor, termasuk perhotelan, makanan dan minuman, ritel, serta industri jasa lainnya. Dalam operasional IFM-nya, YYForce memadukan layanan fasilitas garis depan dengan solusi teknologi yang dirancang untuk meningkatkan produktivitas tenaga kerja dan efisiensi operasional.

Strategi jangka panjang YYForce berfokus pada pembangunan ekosistem tenaga kerja masa depan terintegrasi. Dalam ekosistem ini, kolaborasi antara tenaga kerja manusia, perangkat lunak cerdas, otomatisasi, dan robotika akan terus ditingkatkan untuk memberikan layanan dengan lebih efisien.

Pernyataan Berwawasan ke Depan

Siaran pers ini berisi pernyataan berwawasan ke depan dalam artian yang terkandung di Pasal 27A Securities Act tahun 1933, sebagaimana diubah, dan Pasal 21E Securities Exchange Act tahun 1934, sebagaimana diubah. Perusahaan mendasarkan pernyataan berwawasan ke depan tersebut pada ekspektasi dan proyeksinya mengenai peristiwa di masa depan, yang disusun Perusahaan berdasarkan informasi yang tersedia saat ini bagi Perusahaan. Anda dapat mengidentifikasi pernyataan berwawasan ke depan melalui pernyataan yang tidak bersifat historis, terutama yang menggunakan terminologi seperti "dapat," "seharusnya," "mengharapkan," "mengantisipasi," "mempertimbangkan," "memperkirakan," "meyakini," "merencanakan," "diproyeksikan," "memprediksi," "berpotensi," atau "berharap," atau bentuk negatif dari istilah-istilah ini maupun istilah serupa lainnya. Pernyataan mengenai rencana pengembangan, fitur, jadwal, dan komersialisasi platform Workforce OS serta aplikasi robotika terkait merupakan pernyataan berwawasan ke depan.

Pernyataan berwawasan ke depan mengandung risiko dan ketidakpastian yang melekat sehingga peristiwa di masa depan yang dibahas dalam siaran pers ini mungkin tidak terjadi. Peristiwa dan hasil aktual dapat berbeda secara signifikan serta bergantung pada risiko, ketidakpastian, dan asumsi mengenai Perusahaan dan sejumlah faktor lainnya. Faktor-faktor ini termasuk, tetapi tidak terbatas pada, sasaran dan strategi Perusahaan; pengembangan bisnis, kondisi keuangan, dan hasil operasional Perusahaan di masa mendatang, termasuk peluncuran produk dan layanan baru, perkiraan perubahan pendapatan, biaya, dan pengeluaran Perusahaan, perkiraan pertumbuhan pelanggan, serta permintaan dan penerimaan pasar terhadap produk dan layanan Perusahaan; serta kondisi industri, pasar, dan regulasi, termasuk persaingan, kebijakan dan peraturan pemerintah yang memengaruhi industri Perusahaan, serta faktor lainnya yang dapat memengaruhi kondisi keuangan, likuiditas, dan hasil operasional Perusahaan.

Untuk pembahasan lebih detail mengenai faktor risiko, rujuk dokumen yang diserahkan Perusahaan kepada Komisi Sekuritas dan Bursa, termasuk bagian "Faktor Risiko" dalam laporan tahunan terbaru Perusahaan pada Formulir 20-F, sebagaimana diubah. Pembaca juga harus mempertimbangkan risiko yang dijelaskan dalam pengajuan Perusahaan kepada Komisi Sekuritas dan Bursa AS. YYForce tidak berkewajiban untuk memperbarui pernyataan ini kecuali sebagaimana diwajibkan oleh hukum yang berlaku.

Copyright 2026 GlobeNewswire, Inc.

Clients of EBC Financial Group can now trade from the same app they use to open, fund, and manage their accounts

LONDON, Oct. 23, 2026 (GLOBE NEWSWIRE) -- EBC Financial Group (EBC) has expanded live trading in the EBC App, bringing account management, funding tools, and trade execution together on one mobile platform.

First introduced in stages on 14 September 2026, the trading feature has since been extended to additional markets, with a further rollout recorded on 21 October. Access remains subject to each client's location, account eligibility, and the EBC entity providing the service.

"Our mission is to help our clients trade better by making our platform accessible any time, any anywhere. The EBC App now allows them to monitor their accounts, follow the status of their orders, and manage their exposure without switching between several platforms. Bringing these functions together should make day-to-day account management more straightforward, while keeping trading risks and responsibilities clear," said Andria Phiniefs, Marketing Director, EBC Financial Group.

What Clients Can Do in the App

Clients can view real-time quotes and trade contracts for difference (CFDs), which let them take a position on price moves without owning the underlying asset, across more than 300 forex pairs, commodities, indices, stocks, and exchange-traded funds. They can place market orders, which fill at the current price, or pending orders, which execute only if the price reaches a level they choose. They can also set take-profit and stop-loss levels, which close a position automatically at a chosen gain or loss, cancel orders, and close several positions with a single tap.

These tools let traders set their limits before a trade moves, which matters because CFDs are traded on margin. Leverage magnifies gains and losses alike, and losses can exceed deposits. A stop-loss is not a guarantee either. In fast-moving markets, prices can jump past a chosen level, a move known as a gap, and the order may then fill at a worse price. The order tools, set out when EBC launched the app in July, are there to give traders clearer control over their exposure, not to remove that risk.

One App from Account Opening to Trade

EBC announced the EBC App on 7 July 2026 as an account management platform. Clients could already open an account and complete identity verification in the app, make deposits and withdrawals, and reach 24/7 multilingual support. They could also switch between accounts, with funds, positions, and trading activity synchronised in real time. With live trading added, the same app now covers the final step of placing a trade.

What Happens After the Tap

Through the group's Smart Order Routing Engine, more than 87.6% of EBC orders are filled at a better price than requested. In other words, those orders were filled at a price more favourable to the client than the one quoted when they were placed. EBC's trading environment provides an average execution speed of 20ms, capacity to process 1,000 orders per second, and 98.75% system stability, supported by Tier 4 private leased-line servers across five global financial hubs and 30 data centres worldwide.

Pricing draws on more than 50 bank and non-bank liquidity providers, including J.P. Morgan, UBS, Barclays, and Goldman Sachs. EBC offers raw ECN spreads from 0.0 pips, where the spread is the gap between the buy and sell price, and five levels of market depth, which show the prices and volumes available beyond the best quote.

EBC App Availability

The EBC App, provided by EBC Financial Group (SVG) LLC, is available for iOS and Android through the official download page at https://www.ebc.com/mobile. Trading functionality, instruments, and account services are subject to applicable local requirements and client eligibility.

Forex and CFD trading on margin involve significant risk, including the possibility of rapid losses. Stop-loss instructions may help manage exposure, but they cannot guarantee execution at a particular price. The protections available to clients, including any limits on losses, depend on their contracting entity, account classification, and applicable rules.

Disclaimer: This material is for information only and does not constitute a recommendation or advice from EBC Financial Group and all its entities ("EBC"). Trading Forex and Contracts for Difference (CFDs) on margin carries a high level of risk and may not be suitable for all investors. Losses can exceed your deposits. Before trading, you should carefully consider your trading objectives, level of experience, and risk appetite, and consult an independent financial advisor if necessary. Statistics or past investment performance are not a guarantee of future performance. EBC is not liable for any damages arising from reliance on this information.

About EBC Financial Group

Founded in London and named World Finance's "Best Global Broker" for four years running, EBC Financial Group operates entities regulated by the FCA, ASIC, CIMA, and FSCA, serving over 8 million registered users across more than 100 countries and regions. An Official Partner of FC Barcelona, EBC also champions financial education with the Department of Economics at the University of Oxford, the UN Foundation's United to Beat Malaria programme, and a range of children's charities worldwide through its charity, EBC Group Foundation.

Copyright 2026 GlobeNewswire, Inc.

Ascom completes share capital reduction following share buyback program

Baar, Switzerland, 23 October 2026

Ascom Holding AG has completed the share capital reduction following the share buyback program concluded on 19 June 2026.

The 3,000,000 registered shares repurchased under the share buyback program for the purpose of a subsequent capital reduction have been cancelled, reducing Ascom's share capital accordingly.

Following the cancellation, Ascom's share capital amounts to CHF 16,500,000, divided into 33,000,000 registered shares with a nominal value of CHF 0.50 each.

Further information is available in Ascom's 19 June 2026 announcement on the completion of the share buyback program. Link

Attachment

Ascom_Mediarelease_ShareCapitalReduction

Copyright ? 2026 GlobeNewswire, Inc.

MANILA, Philippines, Oct. 23, 2026 (GLOBE NEWSWIRE) -- The Asian Productivity Organization (APO) convened its 67th Workshop Meeting of Heads of National Productivity Organizations (WSM) in Manila from 20 to 22 October 2026.

The meeting brought together national productivity organization (NPO) Heads and delegates from APO member economies to review progress in implementing Strategic Partnership Program (SPP) Plan activities, exchange experiences, and consider proposals and updates on key APO programs and initiatives under the APO Vision 2030.

The meeting marked a further step in moving the SPP from planning to implementation. NPO Heads shared updates on their respective SPP Plan activities, including progress, approaches, challenges, lessons learned, and opportunities for closer cooperation. The WSM also reviewed SPP Plan activities in 2026 and planned activities for 2027.

The inaugural session featured opening remarks by the APO Director for the Philippines and Secretary of the Department of Economy, Planning, and Development, Dr. Arsenio M. Balisacan; a statement by the APO Secretary-General, Dr. Indra Pradana Singawinata; and an inaugural address by guest of honor Kim Robert C. de Leon, Secretary of the Department of Budget and Management of the Philippines.

In his opening remarks, Dr. Balisacan emphasized the importance of regional cooperation and aligning APO initiatives with national priorities: "APO Vision 2030 sets our shared direction, while the Strategic Partnership Program, or SPP, provides a framework for initiatives aligned with national priorities."

Dr. Indra highlighted SPP implementation as a key focus of the WSM, emphasizing its role in strengthening member ownership, making APO support more member focused, and improving the delivery of measurable results.

Manila holds an important place in the APO's history: It hosted the Second Asian Round Table Productivity Conference in 1960, where the draft convention that became the APO charter was adopted. On 14 April 1961, the Convention establishing the APO was signed in Manila by eight founding members, including the Philippines.

Reflecting on this history, Dr. Indra said, "As the APO celebrates its 65th anniversary this year, it is fitting that we return to Manila not only to reflect on our beginnings but also to consider how the organization should continue to evolve under the APO Vision 2030."

Secretary de Leon placed the discussions in the broader context of the impact of productivity on people's lives. Emphasizing that productivity should ultimately translate into tangible improvements for citizens, he stated, "At the end of the day, the greatest achievement of productivity is prosperity that people can actually feel."

The inaugural session also featured the launch of the APO Guidebook on Green Productivity, the presentation of an APO Accreditation Body certificate recognizing the reaccreditation of the Mongolian Productivity Organization Certification Body for a second term through 5 December 2030, and the signing of a memorandum of understanding between the Department of Budget and Management and the Development Academy of the Philippines for the Public Financial Management Microcredentialing Program for Budget Officers and Analysts.

Other discussions covered the 2025 Annual Project Review, the performance of APO centers of excellence, the APO Liaison Officers' Meeting, and APO Genuine AI Action activities.

On the second day, delegates considered proposals and reports from the APO Secretariat on revisions to the APO Award Program, the proposed establishment of an APO training center, and updates to the APO Accreditation and Certification Program, as part of continuing efforts to strengthen institutional mechanisms under Vision 2030.

Discussions throughout the WSM reflected the priorities of Vision 2030, emphasizing member-driven programming, measurable results, and APO support aligned with member economy priorities.

About the APO

The APO is a regional intergovernmental organization dedicated to improving productivity in the Asia-Pacific region through mutual cooperation. Established in 1961, the APO supports its member economies through policy advisory services, capacity building, and knowledge sharing to promote sustainable socioeconomic development.

Copyright 2026 GlobeNewswire, Inc.

SEOUL, Oct. 23, 2026 (GLOBE NEWSWIRE) -- SECO, merek suku cadang otomotif milik SEOJIN AUTOMOTIVE, menyoroti pengalaman selama enam dekade serta komitmen berkelanjutannya terhadap kualitas, daya tahan, keselamatan, dan nilai yang kompetitif dalam rangka merayakan hari jadinya yang ke-60 pada tahun 2026.

Didirikan pada tahun 1966, SECO telah membangun reputasinya tidak hanya melalui pasokan komponen OEM kepada produsen mobil global, tetapi juga melalui penyediaan suku cadang aftermarket yang dirancang untuk memenuhi kebutuhan distributor, bengkel, dan berbagai pengguna akhir.

Saat ini, SECO Aftermarket menawarkan beragam suku cadang pengganti yang mencakup sistem utama kendaraan, termasuk kopling, kampas rem, komponen suspensi, peredam kejut, sambungan kecepatan konstan (CV Joint), bantalan (bearing), komponen sistem pengapian, serta berbagai komponen penting lainnya.

"Selama 60 tahun, kami telah berupaya menyediakan produk yang dapat diandalkan oleh pelanggan dan mitra bisnis kami. Fokus kami tetap jelas: kualitas produk yang konsisten, kinerja yang andal, dan nilai praktis bagi pasar suku cadang aftermarket otomotif global," tambah SECO.

SECO Aftermarket menerapkan pengendalian kualitas berdasarkan standar OE (Original Equipment) di seluruh rangkaian produknya. Pendekatan ini mendukung konsistensi proses produksi dan pemeriksaan, sekaligus membantu pelanggan memilih suku cadang otomotif aftermarket dengan percaya diri. Dengan menggabungkan cakupan produk yang luas serta fokus pada daya tahan dan keselamatan, SECO bertujuan untuk mendukung pemeliharaan kendaraan yang efisien dan kepuasan pelanggan dalam jangka panjang.

Portofolio produk aftermarket perusahaan dirancang untuk memenuhi kebutuhan yang terus berkembang dari jaringan layanan perawatan dan distribusi otomotif. Produk-produknya dikembangkan untuk memberikan kinerja yang andal dalam kondisi berkendara sehari-hari, sekaligus menawarkan alternatif yang kompetitif bagi perusahaan yang mencari suku cadang pengganti berkualitas dan proses pengadaan yang efisien.

"Pencapaian 60 tahun SECO bukan hanya merupakan perayaan atas sejarah kami, tetapi juga sebuah janji untuk masa depan," tambah SECO. "Kami akan terus membangun kepercayaan melalui kualitas, memperluas rangkaian produk kami, dan menciptakan nilai bagi para mitra di seluruh pasar suku cadang aftermarket otomotif."

SECO Aftermarket mengundang distributor suku cadang otomotif, pembeli suku cadang, bengkel, dan para profesional industri untuk mengetahui lebih lanjut mengenai rangkaian produk serta peluang kemitraan yang ditawarkan.

Untuk informasi lebih lanjut mengenai SECO Aftermarket, silakan lihat informasi berikut.

Situs Web Resmi: https://secoautomotive.com

LinkedIn: https://www.linkedin.com/company/seojinautomotive

Email: amt18200@secoautomotive.com

Katalog Online: www.secoautomotive.co.kr

Copyright 2026 GlobeNewswire, Inc.

Top bartenders from 49 countries competed in Scotland for the coveted title

EDINBURGH, United Kingdom, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Zana Mohlmann from Singapore has been crowned Diageo World Class Global Bartender of the Year 2026 at the world's biggest cocktail competition, taking top place among finalists from six continents.

M?hlmann of East47 at Conrad Singapore Orchard combined technical mastery and creative flair with the warm, intuitive hospitality that defines a truly world class bartender.

Originally from the Netherlands, she found bartending on a gap year in Asia and trained in Amsterdam's bars. She then joined the opening team of Ryan Chetiyawardana's Super Lyan, rising to Head Bartender. She spent months refining every serve in preparation for the Global Finals, dedication that paid off last night in Edinburgh.

Alongside the title, Zana will represent Diageo and its brands in a year-long opportunity to showcase her bartending skills around the world and, for the first time, this year's Global Bartender of the Year will partner with Diageo to create a ready-to-drink cocktail that will launch in multiple markets next year. The title also includes an all-expenses trip to the 2027 World Class Global Final.

A 16-strong international judging panel of well-known leading figures from the global bar industry, including Ago Perrone of London's Connaught Bar, Monica Berg of Tayer + Elementary, and Lorenzo Antinori of Hong Kong's Bar Leone (recently named The World's Best Bar at The 50 Best Bars 2026, for the second consecutive year) judged competitors across a series of live brand challenges (challenges listed in notes to editors, below).

Speaking on behalf of the judging panel, Ago Perrone said:

"My fellow judges and I have been impressed by the dedication and the efforts that have gone into each creation this year. It's always so inspiring to watch the next generation at work, even more so Zana. Zana won us over thanks to the imagination, commitment and real heart she put into the challenges showing the warmth of a true host. And that's what really makes a World Class bartender."

The World Class programme showcases Diageo's commitment to a vibrant hospitality sector, the on-trade and its customers, while creating a space to share insights on the latest drinking trends. Since 2009, the programme has celebrated and nurtured the careers of over 500,000 bartenders.

Kevin Delaney, Global Head of World Class, said:

"World Class is the ultimate toast to the beating heart of the hospitality industry: rockstar bartenders pushing the boundaries of their creativity and skill through competition - hosting tirelessly, serving responsibly and setting the trends we'll all experience in the future. It's a program dedicated to the trade - because when bartenders flourish, the experience is enhanced for everyone. We are delighted to welcome Zana into the Diageo World Class Hall of Fame."

This year, the Global Finals were marked with Scotland Served, a World Class Festival transforming more than 400 venues across the country into destinations for exploration into Scotch Whisky, showcasing a new generation of Scotch cocktails from Johnnie Walker and The Singleton.

Celebrating both the World Class win and her 29th birthday on the same night, Zana Mohlmann World Class Global Bartender of the Year 2026, said:

"It's unbelievable. I don't think I know how to feel yet. I'd let myself imagine this moment a little, but I was almost scared to, and there were moments I didn't think I would win. I've never been so happy, or so surprised."

With the Global Finals on Scottish soil, the judging panel also included Scottish talent, including Iain McPherson of Edinburgh's award-winning Panda & Sons; Andy Gemmell, owner of The Gate pub in Glasgow; and Kaitlin Wilkes, co-founder of The Ada Coleman Project.

The bartender challenges included:

'Community Spirit', Ketel One Vodka high-stakes relay of precision and speed

'The Slow Train', an intimate cocktail and food pairing featuring The Singleton Whisky aboard a private train to the brand's Glen Ord Distillery

'Under Pressure', reimagining Don Julio Tequila as a ready-to-drink, carbonated serve with original label artwork

'Iconology', a head-turning Tanqueray No. TEN Gin cocktail built to command a room

'Fast Forward', a three-drink Johnnie Walker Black Label mixtape flight, each cocktail paired with a music track from [HIS/HER/THEIR] bartending journey.

Assets available: Images of winner, spokesperson for interviews.

WINNER'S BIO

Zana M?hlmann is the Beverage Manager of Manhattan and East47 at Conrad Singapore Orchard. At Manhattan, she builds upon the fvenue's celebrated legacy, honouring the Golden Age of cocktails while evolving its story through innovative menu concepts such as Seasons of Manhattan. At East47, she champions a more experimental approach, pushing creative boundaries while maintaining a relentless focus on flavour and guest experience.

Previously Manhattan's Head Bartender, Zana played a key role in shaping the bar's creative identity while fostering a culture of collaboration, mentorship, and inclusivity. Today, she oversees the beverage vision for both venues, balancing heritage with innovation and strengthening Manhattan's global reputation while establishing East47 as an emerging destination on the international cocktail scene.

Originally from the Netherlands, Zana discovered bartending during a gap year travelling through Asia. She refined her craft in acclaimed Amsterdam bars before joining the opening team of Super Lyan by Ryan Chetiyawardana, rising to Head Bartender.

Her achievements include being crowned in several bartending competitions. Her work has also been featured in Difford's Guide, The Spirits Business, and Drink Magazine Asia. Through creativity, leadership, and an inclusive approach, Zana continues to shape exceptional bar experiences and inspire the global bartending community.

ABOUT WORLD CLASS

World Class is on a mission to inspire people to drink better and create unforgettable experiences in the process. Whether at home or in a bar, World Class encourages consumers to think and care about what, where and how they drink, and in doing so, discover the best of cocktail culture.

World Class has supported, trained and inspired over 500,000 bartenders across the globe over the past seventeen years, while partnering them with the world's finest spirits. It is the authority on the global drinks industry for information on the latest drinks, trends, cocktail recipes and industry insight.

ABOUT DIAGEO

Diageo is a global leader in beverage alcohol with an outstanding collection of brands across spirits and beer categories. These brands include Johnnie Walker, Crown Royal, J&B and Buchanan's whiskies, Smirnoff and Ketel One vodkas, Captain Morgan, Baileys, Don Julio, Tanqueray and Guinness.

Diageo is a global company, and our products are sold in nearly 180 countries around the world. The company is listed on both the London Stock Exchange (DGE) and the New York Stock Exchange (DEO). For more information about Diageo, our people, our brands, and performance, visit us at www.diageo.com. Visit Diageo's global responsible drinking resource, www.DRINKiQ.com for information, initiatives, and ways to share best practice.

Crafting iconic drinks chosen for life's moments.

Copyright 2026 GlobeNewswire, Inc.

SINGAPORE, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Antalpha Platform Holding Company (NASDAQ: ANTA) ("Antalpha"), a leading institutional digital asset financing platform, today announced that its wholly owned subsidiary, Antalpha Capital (HK) Limited, has entered into a share subscription agreement with Aurelion Inc. (NASDAQ: AURE) ("Aurelion" or the "Company").

Under the agreement, Antalpha, through Antalpha Capital (HK) Limited, will subscribe for 952,381 newly issued Class B ordinary shares of Aurelion at a price of US$2.10 per share, for aggregate gross proceeds to Aurelion of approximately US$2 million (the "Subscription"). The Subscription is expected to close as soon as practicable, subject to customary closing conditions and a long-stop date of December 21, 2026.

Antalpha currently holds 31.7% of the ordinary shares of Aurelion's issued and outstanding shares, based on Aurelion's outstanding shares/pre-funded warrants/primary warrants, representing approximately 77.5% of Aurelion's total voting power. Upon completion of the subscription, Antalpha is expected to hold approximately 33.4% of Aurelion's issued and outstanding shares, based on Aurelion's outstanding shares/pre-funded warrants/primary warrants representing approximately 78.8% of Aurelion's total voting rights.

"Increasing our investment in Aurelion reflects our continued confidence in its strategy and the long-term potential of tokenized gold," said Paul Liang, Chief Financial Officer of Antalpha. "Aurelion's focus on digital gold infrastructure complements our expertise in financing and risk management. Through this additional commitment, we are supporting the development of practical institutional applications for tokenized gold, with disciplined execution and long-term shareholder value as our priorities."

"Antalpha's continued support as our controlling shareholder reinforces its commitment to Aurelion's next phase of development," said Frank Zheng, Chief Executive Officer of Aurelion. "Upon closing, this investment would provide additional financial flexibility as we advance our digital gold business. Our focus is on building the technology and risk-management capabilities that institutions need to use tokenized gold with confidence."

About Antalpha

Antalpha is a leading fintech company specializing in providing financing, technology, and risk management solutions to the Web3 industry. Antalpha offers Bitcoin supply chain and margin loans through the Antalpha Prime technology platform, which allows customers to originate and manage their digital assets loans, as well as monitor collateral positions with near real-time data. Building on this foundation, Antalpha is also exploring AI-powered tools to help users navigate the digital asset space more effectively.

About Aurelion

Aurelion is a publicly listed company building a digital gold risk and technology infrastructure around XAU₮, on-chain gold backed by physical LBMA bars. Combining the characteristics of physical gold with the efficiency of blockchain technology, XAU₮ serves as the foundation of Aurelion's digital gold treasury strategy.

The Company is committed to the prudent management and efficient utilization of its proprietary digital gold holdings, while providing risk management and technical support for selected tokenized gold initiatives. Through its technology-driven approach, Aurelion seeks to contribute to the responsible development and broader adoption of digital gold and tokenized asset solutions.

Safe Harbor Statement

This press release contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "aims," "future," "intends," "plans," "believes," "estimates," "likely to," and similar statements. Statements that are not historical facts, including statements about Antalpha's beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties.

Further information regarding these and other risks is included in Antalpha's filings with the SEC. All information provided in this press release is as of the date of this press release, and Antalpha does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Copyright 2026 GlobeNewswire, Inc.

HANOI, VIETNAM - Media OutReach Newswire - 23 October 2026 - Vietnam's healthcare spending is forecast to reach US$34.1 billion by 2028, while most medical equipment, finished medicines and active pharmaceutical ingredients are still imported; at the same time, policy is shifting its focus towards prevention and screening.

Global Health Week Vietnam 2027 takes place against this backdrop, where healthcare facilities, businesses and investors come together to discuss solutions, partnerships and investment in Vietnam.

Resources grow, and so does the need for innovation

Speaking at a workshop of the Health Strategy and Policy Institute on 24 December 2025, Dr Ong The Due said Vietnam's healthcare spending has grown by an average of around 7?8% a year: from US$17.4 billion in 2019 to an estimated US$27.5 billion in 2025, and is forecast to reach US$34.1 billion in 2028.

This growth comes with a shift in the direction of health care. Resolution 72-NQ/TW of the Politburo (September 2025) on protecting, caring for and improving people's health calls for a decisive shift from treatment-centred care to proactive prevention and continuous, life-course health care. Directive 17/CT-TTg of the Prime Minister (May 2026) calls for all citizens to receive a free periodic health check-up or screening at least once a year and to have a personal electronic health record by the end of 2026.

Funding has been allocated: the National Assembly has approved the investment policy for the National Target Programme on health care, population and development for 2026?2035 (Resolution 262/2025/QH15), with total funding of VND 88,635 billion (about US$3.4 billion) for 2026?2030, of which VND 47,692 billion is public investment capital. The second campus of Bach Mai Hospital (1,000 beds) has a 2025 procurement plan of 47 equipment packages worth more than VND 338 billion (about US$13 million).

The professional foundation is in place: Vietnam's essential health service coverage index reached 71 out of 100 in 2023, according to the World Bank; Vietnamese doctors have mastered multi-organ transplantation, fetal cardiac intervention and robotic surgery, performing more than 1,000 organ transplants a year. Yet at many facilities, equipment has not kept pace with the capabilities of the workforce.

The gap is clearly visible in the equipment market: according to the U.S. International Trade Administration (ITA), citing BMI forecasts, Vietnam's medical device market could grow from US$1.9 billion in 2024 to US$2.8 billion in 2029, while around 90% of equipment is still imported. Procurement therefore has to go hand in hand with technical transfer, consumables supply, data integration, maintenance and post-handover support.

The pharmaceutical sector faces a similar challenge: Vietnam imports around 60% of finished medicines and 90% of active pharmaceutical ingredients (ITA), while the National Strategy for Pharmaceutical Industry Development (Decision 1165/QD-TTg of the Prime Minister) targets domestically produced medicines meeting around 80% of demand and 70% of market value by 2030, with domestic raw materials meeting 20% of demand - which calls for manufacturing technology, quality control and technology transfer agreements with clearly defined responsibilities.

International capital is already present: the 2024 Statistical Yearbook records 159 valid FDI projects in health and social assistance, with registered capital of nearly US$1.77 billion. In 2023, Thomson Medical Group completed the acquisition of the company that owns FV Hospital, with an initial payment of US$352.8 million, and Raffles Medical Group signed a conditional agreement to acquire a controlling stake in and participate in the management of the American International Hospital in Ho Chi Minh City; AstraZeneca has committed to invest US$360 million in Vietnam through 2030.

From hospital needs to technology choices

Rising demand, expanding capital flows and the push for higher service quality are opening opportunities in Vietnam for global technology, infrastructure and solution providers; the next challenge is choosing the right solutions and putting them into operation. Global Health Week Vietnam 2027 takes place from 5 to 7 April 2027 at the Vietnam Exposition Center (VEC), Hanoi, co-organised by VEC and dmg events, and comprises three concurrent specialised exhibitions and conferences: Global Health Week Vietnam 2027 (health systems and care delivery), Laboratory & Diagnostics Vietnam 2027 (laboratory and diagnostics) and BioPharma Vietnam 2027 (pharmaceuticals and biotechnology).

The event targets around 30,000 attendees from more than 120 countries, including healthcare leaders, clinicians, administrators and decision-makers, among them 3,000 conference delegates; more than 500 exhibitors, more than 10 country pavilions and more than 300 domestic and international speakers.

Global Health Week Vietnam 2027 presents solutions in hospital infrastructure, operations, digital health, AI, preventive care and population health, alongside the high-level Global Health Week Vietnam Forum on health policy and investment, and the Innovation Theatre showcasing technology.

Laboratory & Diagnostics Vietnam 2027 addresses the need to strengthen testing capacity as screening expands, with the Diagnostics Innovation Zone covering molecular diagnostics, point-of-care technologies and AI-driven laboratory systems. BioPharma Vietnam 2027 focuses on manufacturing technology, quality standards and technology transfer, with Partnership & Investment Meetings bringing together manufacturers, investors and technology partners.

A need may begin at a patient's bedside, while the answer may lie half a world away from Vietnam. With fast-growing demand, capital already in place and an increasingly clear role in Asia's healthcare supply chain, Vietnam is a market that international suppliers are turning to. Global Health Week Vietnam 2027 creates more face-to-face meetings to close that distance: bringing technology closer to Vietnam's hospitals and patients and, from Vietnam, helping shape the future of healthcare in Asia.

Details and stand booking are available on each exhibition's website:

- Global Health Week Vietnam 2027: https://www.globalhealthweek-vietnam.com/

- Laboratory & Diagnostics Vietnam 2027: https://laboratoryandiagnostics-vietnam.com/

- BioPharma Vietnam 2027: https://biopharma-vietnam.com/

About the Vietnam Exposition Center (VEC)

The Vietnam Exposition Center (VEC) in Dong Anh, Hanoi is an international-standard exhibition and convention complex with a total area of around 900,000 m?, comprising indoor exhibition halls, outdoor squares, a convention centre, a theatre and stadiums. VEC hosted the National Achievements Exhibition 2025, which welcomed more than 10 million visitors in 19 days, and specialised trade weeks such as Vietnam Industry and Technology Week 2026 (VITW 2026).

Website: https://vec.global/

About dmg events

Founded in 1989, dmg events organises more than 80 events a year in more than 20 countries, attracting over 1 million visitors and delegates, with flagship events including ADIPEC, Gastech, EGYPES, Big 5 Global and Abu Dhabi Global Health Week. Website: https://www.dmgevents.com/

The issuer is solely responsible for the content of this announcement.

Hashtags: #VEC

*Clera Cera is a new science-led dermatological skincare brand, with nine products for everyday use.

*Co-developed with Singapore's National Skin Centre, a member of NHG Health, with ingredients that fortify the Asian skin's natural barrier and lightweight textures suited to Asia's heat, humidity and pollution.

*Its Skin Barrier Resilience System combines Derma-Clera, powered by Cynanchum Atratum (Bai Wei) extract, with five skin-identical ceramides to Replenish, Repair and Relieve Asian skin.

*Clera Cera was shaped by listening sessions and usage tests from more than 18,000 consumers across five Asian markets

HONG KONG SAR - Media OutReach Newswire - 23 October 2026 - Clera Cera, a new science-led dermatological skincare brand made for Asian skin and designed for everyday use, launches today at Guardian and Mannings. Co-developed with an expert team from Singapore's National Skin Centre, a member of NHG Health, Clera Cera brings dermatologist-developed skin barrier care into everyday retail.

Heat, humidity and pollution can take a toll on Asian skin, and everyday habits such as frequent cleansing and use of harsh products strain the skin barrier. Research1 also suggests that Asian skin has a thinner outer layer, which makes the barrier more vulnerable to irritants. With about one in three people in Asia reported to have sensitive skin2, the need for skincare designed for these realities is growing.

The launch of Clera Cera comes amid growing consumer demand across Asia for skincare that soothes sensitive skin, supports daily preventive care and is both science-backed and accessible. Clera Cera's mission is simple: to make effective, dermatologist-developed skincare designed for Asian skin part of everyone's daily routine.

"Clera Cera marks a new chapter for Guardian and Mannings. We are going beyond selling health and wellness products to creating them, with the clinical expertise of NHG Health's National Skin Centre behind us. It takes dermatology beyond clinical walls to a shelf where customers already shop, at a price that fits an everyday routine. This is the one of the many ways we continue to democratise wellness and it's what being our customers' Trusted Wellness Advisor means," said Curtis Liu, Chief Executive Officer, Health and Beauty, DFI Retail Group.

Clera Cera is the first initiative focused on dermatological skin care under the long-term partnership between DFI Retail Group and NHG Health announced in October 2025 to strengthen preventive care and widen access to everyday health and wellness. It is the first time a public healthcare cluster in Singapore has worked with a retailer to make safe and effective health solutions backed by clinical research even more accessible to the public in Singapore and across Asia.

"One of NHG Health's mission is to enhance the health of the population we serve. Partnerships like this allow us to translate clinical knowledge and research into everyday health. What makes this collaboration with DFI Retail Group meaningful is that we are able to bring evidence-based care to people where they are, beyond the hospital and clinic. Skin health is only the starting point. The wider opportunity is in areas such as elderly nutrition and home care, which will be explored for our ageing population," said Professor Benjamin Seet, Group Chairman Medical Board (Research), NHG Health.

A Science-led Skin Barrier Resilience System to Replenish, Repair and Relieve Asian Skin

Clera Cera was co-developed with a leading dermatology team at Singapore's National Skin Centre, a member of NHG Health. Associate Professor Tey Hong Liang, who led the formulation of it with Ms. Winnie Choo, Principal Pharmacist, is ranked among the world's top 2% of scientists by Stanford University and Elsevier. The team's work spans more than 55 healthcare-related national and international awards, grants and fellowships for advancing skin health.

The core essence of Clera Cera's formulation is a Skin Barrier Resilience System that combines two key components:

Derma-Clera, powered by Cynanchum Atratum (Bai Wei) botanical extract, that helps soothe the skin;

Five skin-identical ceramides that help replenish essential lipids within the skin barrier, supporting hydration, repair and strength.

Working like building blocks, they help reinforce the Asian skin's natural barrier by supporting healthy barrier in three ways:

Replenish: Restores skin hydration, with moisture-attracting ingredients such as saccharide isomerate

Repair: Strengthens the skin barrier with five skin-identical ceramides

Relieve​: Soothes the skin with Derma-Clera, ​powered by a Cynanchum Atratum (Bai Wei) extract.

"Exposure to pollution and a warm, humid climate, together with frequent cleansing and use of harsh products weaken the protective barrier of the Asian skin over time. In our clinics, we often see this in patients with sensitive skin. The barrier depends on natural lipids such as ceramides, and it is best supported by gentle, consistent care, using lightweight formulations that people find comfortable applying every day,"said Associate Professor Tey Hong Liang, Clinical Director of the Centre for MedTech and Innovations, NHG Health, and Senior Consultant Dermatologist, National Skin Centre.

Made for Asian skin with feedback from Asian consumers

Shaped by listening sessions and usage tests from more than 18,000 consumers across Hong Kong, Indonesia, Malaysia, Singapore and Vietnam, Clera Cera overcomes common frustrations such as use of artificial fragrances and having sticky textures. The affordable, clean formula is designed for sensitive skin in humid climates.

The nine-product range spans body, face, targeted serums, and sun care made for Asian skin. Clera Cera is available now in Singapore, exclusively at Guardian Health & Beauty stores and online, and selected NHG Health pharmacies. Rollout in Brunei, Chinese mainland, Hong Kong, Indonesia, Malaysia, Macau and Vietnam will follow, reaching eight markets across Asia, at more than 1,500 Guardian and Mannings stores and online.

Body Care

The lineup features the Gentle Hydrating Cleanser alongside the Skin Relief Moisturising Lotion, both suitable for sensitive, eczema-prone skin and babies from three months old. Both are formulated with the ingredient, saccharide isomerate, which provides 24-hour hydration in the non-soap cleaner and 72-hour hydration in the lotion. In a home user trial involving 104 participants, 89% of panellists agree that the lotion soothes skin in just three minutes.

Face Care

Daily facial care includes the Micellar Water Gentle Makeup Remover, Hydrating Foaming Face Wash, and Barrier Hydrating Aqua Cream. Engineered to prevent clogged pores in humid climates, the line removes waterproof makeup with micellar water while the foaming wash and aqua cream containing the ingredient saccharide isomerate delivers up to 24 hours and 72 hours of skin-balancing moisture respectively.

Target Serums

Intensive treatment is delivered through the B3 TXA Brightening Dark Spot Serum and Retinol Age Defense Serum. These contain active ingredients that target specific skin concerns while supporting the skin barrier.

Suncare

Broad-spectrum protection features two mineral formulas: the Daily Defense Physical Sunscreen Serum SPF 50 PA+++ and the Tone Up Physical Sunscreen Serum SPF 50 PA+++. Powered by Nano Zinc Oxide, both sunscreens reflect UVA/UVB rays and block 95% of blue light, featuring 40-minute water resistance.

[1] Infant Skin Barrier, Structure, and Enzymatic Activity Differ from Those of Adult in an East Asian Cohort. BioMed Research International. 2018. Liu Q, Zhang Y, Danby SG, Cork MJ, Stamatas GN.

[2] Chen W, Dai R, Li L. The prevalence of self-declared sensitive skin: a systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology. 2020;34(8):1779-1788. DOI: 10.1111/jdv.16166 Meta-analysis comprising 26 studies and 51,783 participants globally, with a pooled Asian prevalence of 31% (95% CI 16?45%).

Clera Cera

Clera Cera is a science-led dermatological skincare brand made for Asian skin. Co-developed with the National Skin Centre, NHG Health, Singapore, the brand combines deep Asian skin expertise with dermatological science to deliver effective yet gentle care for everyday Asian life. Its Skin Barrier Resilience System is designed to support the way Asian skin naturally repairs itself, helping to replenish, repair and relieve for a strong, resilient Asian skin barrier.

The issuer is solely responsible for the content of this announcement.

Hashtags: #cleracera #Guardian #Mannings #dermatologist #skincare